

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number  
WO 2005/054430 A2

(51) International Patent Classification<sup>7</sup>: C12N

(21) International Application Number:  
PCT/US2004/038967

(22) International Filing Date:  
19 November 2004 (19.11.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/523,764 20 November 2003 (20.11.2003) US

(71) Applicant (for all designated States except US): BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): TU, Yong [CN/US]; 1041 Danard Place, Cheshire, Connecticut 06410 (US). SCOLA, Paul, Michael [US/US]; 107 Georgetown Drive, Glastonbury, Connecticut 06033 (US). GOOD, Andrew, Charles [GB/US]; 52 High Hill Road, Wallingford, Connecticut 06492 (US). CAMPBELL, Jeffrey, Allen [US/US]; 31 Bell Avenue, Glen Gardner, New Jersey 08826 (US).

(74) Agents: VOLLES, Warren, K. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,

GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,

[Continued on next page]

(54) Title: HEPATITIS C VIRUS INHIBITORS



(57) Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: (I) wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

WO 2005/054430 A2



- CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
  - as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
  - as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
  - as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
  - as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- Published:**
- without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## HEPATITIS C VIRUS INHIBITORS

### FIELD OF THE INVENTION

5           The present invention is generally directed to antiviral compounds, and more specifically directed to compounds which inhibit the functioning of the NS3 protease (also referred to herein as "serine protease") encoded by Hepatitis C virus (HCV), compositions comprising such compounds and methods for inhibiting the functioning of the NS3 protease.

10

### BACKGROUND OF THE INVENTION

HCV is a major human pathogen, infecting an estimated 170 million persons worldwide - roughly five times the number infected by human immunodeficiency virus type 1. A substantial fraction of these HCV infected individuals develop serious progressive liver disease, including cirrhosis and hepatocellular carcinoma. (Lauer, G. M.; Walker, B. D. *N. Engl. J. Med.* (2001), 345, 41-52).

Presently, the most effective HCV therapy employs a combination of alpha-interferon and ribavirin, leading to sustained efficacy in 40% of patients. (Poynard, T. et al. *Lancet* (1998), 352, 1426-1432). Recent clinical results demonstrate that pegylated alpha-interferon is superior to unmodified alpha-interferon as monotherapy (Zeuzem, S. et al. *N. Engl. J. Med.* (2000), 343, 1666-1672). However, even with experimental therapeutic regimens involving combinations of pegylated alpha-interferon and ribavirin, a substantial fraction of patients do not have a sustained reduction in viral load. Thus, there is a clear and long-felt need to develop effective therapeutics for treatment of HCV infection.

HCV is a positive-stranded RNA virus. Based on a comparison of the deduced amino acid sequence and the extensive similarity in the 5' untranslated region, HCV has been classified as a separate genus in the Flaviviridae family. All members of the Flaviviridae family have enveloped virions that contain a positive

stranded RNA genome encoding all known virus-specific proteins via translation of a single, uninterrupted, open reading frame.

5 Considerable heterogeneity is found within the nucleotide and encoded amino acid sequence throughout the HCV genome. At least six major genotypes have been characterized, and more than 50 subtypes have been described. The major genotypes of HCV differ in their distribution worldwide, and the clinical significance of the genetic heterogeneity of HCV remains elusive despite numerous studies of the possible effect of genotypes on pathogenesis and therapy.

10


The single strand HCV RNA genome is approximately 9500 nucleotides in length and has a single open reading frame (ORF) encoding a single large polyprotein of about 3000 amino acids. In infected cells, this polyprotein is cleaved at multiple sites by cellular and viral proteases to produce the structural and non- structural (NS) 15 proteins. In the case of HCV, the generation of mature non-structural proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) is effected by two viral proteases. The first one is believed to cleave at the NS2-NS3 junction; the second one is a serine protease contained within the N-terminal region of NS3 and mediates all the subsequent cleavages downstream of NS3, both in cis, at the NS3-NS4A cleavage site, and in 20 trans, for the remaining NS4A- NS4B, NS4B-NS5A, NS5A-NS5B sites. The NS4A protein appears to serve multiple functions, acting as a cofactor for the NS3 protease and possibly assisting in the membrane localization of NS3 and other viral replicase components. The complex formation of the NS3 protein with NS4A seems necessary to the processing events, enhancing the proteolytic efficiency at all of the sites. The 25 NS3 protein also exhibits nucleoside triphosphatase and RNA helicase activities. NS5B is a RNA-dependent RNA polymerase that is involved in the replication of HCV.

30 Among the compounds that have demonstrated efficacy in inhibiting HCV replication, as selective HCV serine protease inhibitors, are the peptide compounds disclosed in U.S. Patent No. 6,323,180.

**SUMMARY OF THE INVENTION**

The present invention provides compounds of formula I;

5



wherein:

- (a)  $R_1$  is Het or aryl;
- 10 (b)  $m$  is 1 or 2;
- (c)  $n$  is 1 or 2;
- (d)  $R_2$  is H; or  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{3-7}$  cycloalkyl, each optionally substituted with halogen;
- (e)  $R_3$  is  $C_{1-8}$  alkyl optionally substituted with halo, cyano, amino,  $C_{1-6}$  dialkylamino,  $C_{6-10}$  aryl,  $C_{7-14}$  alkylaryl,  $C_{1-6}$  alkoxy, carboxy, hydroxy, aryloxy,  $C_{7-14}$  alkylaryloxy,  $C_{2-6}$  alkylester or  $C_{8-15}$  alkylarylester;  $C_{3-12}$  alkenyl,  $C_{3-7}$  cycloalkyl, or  $C_{4-10}$  alkylcycloalkyl, wherein the cycloalkyl or alkylcycloalkyl are optionally substituted with hydroxy,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{1-6}$  alkoxy; or  $R_3$  together with the carbon atom to which it is attached forms a  $C_{3-7}$  cycloalkyl group optionally substituted with  $C_{2-6}$  alkenyl;
- 15
- 20 (f)  $Y$  is H, phenyl substituted with nitro, pyridyl substituted with nitro, or  $C_{1-6}$  alkyl optionally substituted with cyano, OH or  $C_{3-7}$  cycloalkyl; provided that if  $R_4$  or  $R_5$  is H then  $Y$  is H;
- 25 (g)  $B$  is H,  $C_{1-6}$  alkyl,  $R_4-(C=O)-$ ,  $R_4O(C=O)-$ ,  $R_4-N(R_5)-C(=O)-$ ,  $R_4-N(R_5)-C(=S)-$ ,  $R_4SO_2-$ , or  $R_4-N(R_5)-SO_2-$ ;

- (h)  $R_4$  is (i)  $C_{1-10}$  alkyl optionally substituted with phenyl, carboxyl,  $C_{1-6}$  alkanoyl, 1-3 halogen, hydroxy,  $-OC(O)C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amino optionally substituted with  $C_{1-6}$  alkyl, amido, or (lower alkyl) amido; (ii)  $C_{3-7}$  cycloalkyl,  $C_{3-7}$  cycloalkoxy, or  $C_{4-10}$  alkylcycloalkyl, each optionally substituted with hydroxy, carboxyl, ( $C_{1-6}$  alkoxy)carbonyl, amino optionally substituted with  $C_{1-6}$  alkyl, amido, or (lower alkyl) amido; (iii)  $C_{6-10}$  aryl or  $C_{7-16}$  arylalkyl, each optionally substituted with  $C_{1-6}$  alkyl, halogen, nitro, hydroxy, amido, (lower alkyl) amido, or amino optionally substituted with  $C_{1-6}$  alkyl; (iv) Het; (v) bicyclo(1.1.1)pentane; or (vi)  $-C(O)OC_{1-6}$  alkyl,  $C_{2-6}$ alkenyl or  $C_{2-6}$  alkynyl;
- (i)  $R_5$  is H;  $C_{1-6}$  alkyl optionally substituted with 1-3 halogens; or  $C_{1-6}$  alkoxy provided  $R_4$  is  $C_{1-10}$  alkyl;
- (j) X is O, S, SO,  $SO_2$ ,  $OCH_2$ ,  $CH_2O$  or NH;
- (k)  $R'$  is Het,  $C_{6-10}$  aryl or  $C_{7-14}$  alkylaryl, each optionally substituted with  $R^a$ ; and
- (l)  $R^a$  is  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl,  $C_{1-6}$  alkoxy,  $C_{3-7}$  cycloalkoxy, halo- $C_{1-6}$  alkyl,  $CF_3$ , mono-or di- halo- $C_{1-6}$  alkoxy, cyano, halo, thioalkyl, hydroxy, alkanoyl,  $NO_2$ , SH, , amino,  $C_{1-6}$  alkylamino, di ( $C_{1-6}$ ) alkylamino, di ( $C_{1-6}$ ) alkylamide, carboxyl, ( $C_{1-6}$ ) carboxyester,  $C_{1-6}$  alkylsulfone,  $C_{1-6}$  alkylsulfonamide, di ( $C_{1-6}$ ) alkyl(alkoxy)amine,  $C_{6-10}$  aryl,  $C_{7-14}$  alkylaryl, or a 5-7 membered monocyclic heterocycle;
- or a pharmaceutically acceptable enantiomer, diastereomer, salt, solvate or prodrug thereof.

The present invention also provides compositions comprising the compounds or pharmaceutically acceptable salts, solvates or prodrugs thereof and a pharmaceutically acceptable carrier. In particular, the present invention provides pharmaceutical compositions useful for inhibiting HCV NS3 comprising a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier.

The present invention further provides methods for treating patients infected with HCV, comprising administering to the patient a therapeutically effective amount of a compound of the present invention, or a pharmaceutically acceptable salt, solvate or prodrug thereof. Additionally, the present invention provides methods of  
5 inhibiting HCV NS3 protease by contacting the NS3 protease with a compound of the present invention.

By virtue of the present invention, it is now possible to provide improved  
10 drugs comprising the compounds of the invention which can be effective in the treatment of patients infected with HCV. Specifically, the present invention provides peptide compounds that can inhibit the functioning of the NS3 protease, e.g., in combination with the NS4A protease. Further, the present invention makes it possible to administer combination therapy to a patient whereby a compound in  
15 accordance with the present invention, which is effective to inhibit the HCV NS3 protease, can be administered with another compound having anti-HCV activity, e.g., a compound which is effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV  
20 NS5A protein, IMPDH and a nucleoside analog for the treatment of an HCV infection.

### **DETAILED DESCRIPTION OF THE INVENTION**

25

Stereochemical definitions and conventions used herein generally follow McGraw-Hill Dictionary of Chemical Terms, S. P. Parker, Ed., McGraw-Hill Book Company, New York (1984) and Stereochemistry of Organic Compounds, Eliel, E. and Wilen, S., John Wiley & Sons, Inc., New York (1994). Many organic  
30 compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are employed

to designate the sign of rotation of plane-polarized light by the compound, with (-) or  
1 meaning that the compound is levorotatory and (+) or d, meaning the compound, is  
dextrorotatory. For a given chemical structure, these compounds, called  
stereoisomers, are identical except that they are mirror images of one another. A  
5 specific stereoisomer of a mirror image pair may also be referred to as an enantiomer,  
and a mixture of such isomers is often called an enantiomeric mixture. With  
reference to the instances where (R) or (S) is used, it is to designate the absolute  
configuration of a substituent in context to the whole compound and not in context to  
the substituent alone.

10

Unless otherwise specifically noted herein, the terms set forth below will have  
the following definitions.

The terms "racemic mixture" and "racemate" refer to an equimolar mixture of  
15 two enantiomeric species, devoid of optical activity.

The term "chiral" refers to molecules which have the property of non-  
superimposability of the mirror image partner, while the term "achiral" refers to  
molecules which are superimposable on their mirror image partner.

20

The term "stereoisomers" refers to compounds which have identical chemical  
composition, but differ with regard to the arrangement of the atoms or groups in  
space.

25 The term "diastereomer" refers to a stereoisomer which is not an enantiomer,  
e.g., a stereoisomer with two or more centers of chirality and whose molecules are  
not mirror images of one another. Diastereomers have different physical properties,  
e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of  
diastereomers may separate under high resolution analytical procedures such as  
30 electrophoresis and chromatography.

The term "enantiomers" refers to two stereoisomers of a compound which are  
non-superimposable mirror images of one another.

The term "pharmaceutically acceptable salt" is intended to include nontoxic salts synthesized from a compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in *Remington's Pharmaceutical Sciences*, 18th ed., Mack Publishing Company, Easton, PA, 1990, p. 1445. The compounds of the present invention are useful in the form of the free base or acid or in the form of a pharmaceutically acceptable salt thereof. All forms are within the scope of the invention.

The term "therapeutically effective amount" means the total amount of each active component that is sufficient to show a meaningful patient benefit, e.g., a sustained reduction in viral load. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

The term "compounds of the invention", and equivalent expressions, are meant to embrace compounds of formula I, and pharmaceutically acceptable enantiomer, diastereomer salts, and solvates, e.g. hydrates, and prodrugs. Similarly, references to intermediates, are meant to embrace their salts, and solvates, where the context so permits. References to the compound of the invention also include the preferred compounds, e.g. formula II and A-M.

The term "derivative" means a chemically modified compound wherein the modification is considered routine by the ordinary skilled chemist, such as an ester or an amide of an acid, protecting groups, such as a benzyl group for an alcohol or thiol, and tert-butoxycarbonyl group for an amine.

The term "solvate" means a physical association of a compound of this invention with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are  
5 incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolable solvates. Exemplary solvates include hydrates, ethanulates, methanulates, isopropanulates and the like.

The term "prodrug" as used herein means derivatives of the compounds of the  
10 invention which have chemically or metabolically cleavable groups and become, by solvolysis or under physiological conditions, the compounds of the invention which are pharmaceutically active in vivo. A prodrug of a compound may be formed in a conventional manner with a functional group of the compounds such as with an amino, hydroxy or carboxy group when present. The prodrug derivative form often  
15 offers advantages of solubility, tissue compatibility, or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent  
20 acid compound with a suitable amine.

The term "patient" includes both human and other mammals.

The term "pharmaceutical composition" means a composition comprising a  
25 compound of the invention in combination with at least one additional pharmaceutical carrier, i.e., adjuvant, excipient or vehicle, such as diluents, preserving agents, fillers, flow regulating agents, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and  
30 dispensing agents, depending on the nature of the mode of administration and dosage forms. Ingredients listed in Remington's Pharmaceutical Sciences, 18<sup>th</sup> ed., Mack Publishing Company, Easton, PA (1999) for example, may be used.

The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without excessive toxicity, irritation, allergic response, or other problem or  
5 complication commensurate with a reasonable risk/benefit ratio.

The term "treating" refers to: (i) preventing a disease, disorder or condition from occurring in a patient which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it; (ii) inhibiting the disease,  
10 disorder or condition, i.e., arresting its development; and (iii) relieving the disease, disorder or condition, i.e., causing regression of the disease, disorder and/or condition.

The term "substituted" as used herein includes substitution at from one to the  
15 maximum number of possible binding sites on the core, e.p., organic radical, to which the substituent is bonded, e.g., mono-, di-, tri- or tetra- substituted, unless otherwise specifically stated.

The nomenclature used to describe organic radicals, e.g., hydrocarbons and  
20 substituted hydrocarbons, generally follows standard nomenclature known in the art, unless otherwise specifically defined. Combinations of groups, e.g., alkylalkoxyamine or arylalkyl, include all possible stable configurations, unless otherwise specifically stated. Certain radicals and combinations are defined below for purposes of illustration.

25

The term "halo" as used herein means a halogen substituent selected from bromo, chloro, fluoro or iodo. The term "haloalkyl" means an alkyl group that is substituted with one or more halo substituents.

30

The term "alkyl" as used herein means acyclic, straight or branched chain alkyl substituents having the specified number of carbon atoms and includes, for example, methyl, ethyl, propyl, butyl, tert-butyl, hexyl, 1-methylethyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl. Thus, C<sub>1-6</sub> alkyl refers to an alkyl

group having from one to six carbon atoms. The term "lower alkyl" means an alkyl group having from one to six, preferably from one to four carbon atoms. The term "alkylester" means an alkyl group additionally containing an ester group. Generally, a stated carbon number range, e.g., C<sub>2-6</sub> alkylester, includes all of the carbon atoms in  
5 the radical.

The term "alkenyl" as used herein means an alkyl radical containing at least one double bond, e.g., ethenyl (vinyl) and alkyl.

10 The term "alkoxy" as used herein means an alkyl group with the indicated number of carbon atoms attached to an oxygen atom. Alkoxy includes, for example, methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy and 1,1-dimethylethoxy. The latter radical is referred to in the art as tert-butoxy. The term "alkoxycarbonyl" means an alkoxy group additionally containing a carbonyl group.


15 The term "cycloalkyl" as used herein means a cycloalkyl substituent containing the indicated number of carbon atoms and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and spiro cyclic groups such as spirocyclopropyl or spirocyclobutyl. The term "cycloalkoxy" as used herein  
20 means a cycloalkyl group linked to an oxygen atom, such as, for example, cyclobutyloxy or cyclopropyloxy. The term "alkylcycloalkyl" means a cycloalkyl group linked to an alkyl group. The stated carbon number range includes the total number of carbons in the radical, unless otherwise specifically stated. This a C<sub>4-10</sub> alkylcycloalkyl may contain from 1-7 carbon atoms in the alkyl group and from 3-9  
25 carbon atoms in the ring, e.g., cyclopropylmethyl or cyclohexylethyl.

The term "aryl" as used herein means an aromatic moiety containing the indicated number of carbon atoms, such as, but not limited to phenyl, indanyl or naphthyl. For example, C<sub>6-10</sub> aryl refers to an aromatic moiety having from six to ten  
30 carbon atoms which may be in the form of a monocyclic or bicyclic structure. The term "haloaryl" as used herein refers to an aryl mono, di or tri substituted with one or more halogen atoms. The terms "alkylaryl", "aryllalkyl" and "arylalkyl" mean an aryl group substituted with one or more alkyl groups. Unless the carbon range of each

group is specified, the stated range applies to the entire substituent. Thus, a C<sub>7-14</sub> alkylaryl group may have from 1-8 carbon atoms in the alkyl group for a monocyclic aromatic and from 1-4 carbon atoms in the alkyl group for a fused aromatic. The attachment of the group to bonding site on the molecule can be either at the aryl group or the alkyl group. Unless a specific aryl radical is specified, e.g., fluoro-phenyl, or the radical is stated to be unsubstituted, the aryl radicals include those substituted with typical substituents known to those skilled in the art, e.g., halogen, hydroxy, carboxy, carbonyl, nitro, sulfo, amino, cyano, dialkylamino haloalkyl, CF<sub>3</sub>, haloalkoxy, thioalkyl, alkanoyl, SH, alkylamino, alkylamide, dialkylamide, carboxyester, alkylsulfone, alkylsulfonamide and alkyl(alkoxy)amine. Examples of alkylaryl groups include benzyl, butylphenyl and 1-naphthylmethyl.

The term "alkanoyl" as used herein means straight or branched 1-oxoalkyl radicals containing the indicated number of carbon atoms and includes, for example, formyl, acetyl, 1-oxopropyl (propionyl), 2-methyl-1-oxopropyl, 1-oxohexyl and the like.

The term "alkylamide" as used herein means an amide mono-substituted with an alkyl, such as




The term "heterocycle", also referred to as "Het", as used herein means 7-12 membered bicyclic heterocycles and 5-9 membered monocyclic heterocycles.

Preferred bicyclic heterocycles are 7-12 membered fused bicyclic ring systems (both rings share an adjacent pair of atoms) containing from one to four heteroatoms selected from nitrogen, oxygen and sulfur, wherein one or both rings of the heterocycle can be saturated, partially saturated or fully unsaturated ring system (this latter subset also herein referred to as unsaturated heteroaromatic). The nitrogen

and sulfur heteroatoms atoms may be optionally oxidized. The bicyclic heterocycle may contain the heteroatoms in one or both rings. Unless a specific heterocycle is specified, e.g., a fluorinated 7-12 membered bicyclic heterocycle, or the heterocycle is stated to be unsubstituted, the heterocycles include those substituted with typical  
 5 substituents known to those skilled in the art. For example, the bicyclic heterocycle may also contain substituents on any of the ring carbon atoms, e.g., one to three substituents. Examples of suitable substituents include C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-6</sub> alkoxy, C<sub>3-7</sub> cycloalkoxy, halo-C<sub>1-6</sub> alkyl, CF<sub>3</sub>, mono- or di- halo-C<sub>1-6</sub> alkoxy, cyano, halo, thioalkyl, hydroxy, alkanoyl, NO<sub>2</sub>, SH, , amino, C<sub>1-6</sub> alkylamino, di  
 10 (C<sub>1-6</sub>) alkylamino, di (C<sub>1-6</sub>) alkylamide, carboxyl, (C<sub>1-6</sub>) carboxyester, C<sub>1-6</sub> alkylsulfone, C<sub>1-6</sub> alkylsulfonamide, C<sub>1-6</sub> alkylsulfoxide, di (C<sub>1-6</sub>) alkyl(alkoxy)amine, C<sub>6-10</sub> aryl, C<sub>7-14</sub> alkylaryl, and a 5-7 membered monocyclic heterocycle. When two substituents are attached to vicinal carbon atoms of the bicyclic heterocycle, they can join to form a ring, e.g., a five, six or seven membered ring system containing up to  
 15 two heteroatoms selecting from oxygen and nitrogen. The bicyclic heterocycle may be attached to the molecule, e.g. R<sub>1</sub> in formula I, at any atom in the ring and preferably carbon.

Examples of bicyclic heterocycles include, but are not limited to,  
 20 the following ring systems:




Preferred monocyclic heterocycles are 5-9 membered saturated, partially  
 25 saturated or fully unsaturated ring system (this latter subset also herein referred to as unsaturated heteroaromatic) containing in the ring from one to four heteroatoms selected from nitrogen, oxygen and sulfur, wherein the sulfur and nitrogen heteroatoms may be optionally oxidized. Unless a specific heterocycle is specified, e.g., a C<sub>1-6</sub> alkoxy substituted 5-7 membered monocyclic heterocycle, or the

heterocycle is stated to be unsubstituted, the heterocycles include those substituted with typical substituents known to those skilled in the art. For example, the monocyclic heterocycle may also contain substituents on any of the ring atoms, e.g., one to three substituents. Examples of suitable substituents include C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-6</sub> alkoxy, C<sub>3-7</sub> cycloalkoxy, halo-C<sub>1-6</sub> alkyl, CF<sub>3</sub>, mono- or di- halo-C<sub>1-6</sub> alkoxy, cyano, halo, thioalkyl, hydroxy, alkanoyl, NO<sub>2</sub>, SH, , amino, C<sub>1-6</sub> alkylamino, di (C<sub>1-6</sub>) alkylamino, di (C<sub>1-6</sub>) alkylamide, carboxyl, (C<sub>1-6</sub>) carboxyester, C<sub>1-6</sub> alkylsulfone, C<sub>1-6</sub> alkylsulfoxide, C<sub>1-6</sub> alkylsulfonamide, di (C<sub>1-6</sub>) alkyl(alkoxy)amine, C<sub>6-10</sub> aryl, C<sub>7-14</sub> alkylaryl and an additional 5-7 membered monocyclic heterocycle.

10 The monocyclic heterocycle may be attached to the molecule, e.g. R<sub>1</sub> in formula I, at any atom in the ring.

Examples of monocyclic heterocycles include, but are not limited to, the following (and their tautomers):



15

Those skilled in the art will recognize that the heterocycles used in the compounds of the present invention should be stable. Generally, stable compounds are those which can be synthesized, isolated and formulated using techniques known to those skilled in the art without degradation of the compound.

20

The term "substituent" with reference to an amino acid or amino acid derivative means a radical derived from the corresponding  $\alpha$ -amino acid. For instance, the substituents methyl, iso-propyl, and phenyl represent the amino acids alanine, valine, and phenyl glycine, respectively.

25


Where used in naming compounds of the present invention, the designations "P1', P1, P2, P3 and P4", as used herein, map the relative positions of the amino acid residues of a protease inhibitor binding relative to the binding of the natural peptide cleavage substrate. Cleavage occurs in the natural substrate between P1 and P1'

5 where the nonprime positions designate amino acids starting from the C-terminus end of the peptide natural cleavage site extending towards the N-terminus; whereas, the prime positions emanate from the N-terminus end of the cleavage site designation and extend towards the C-terminus. For example, P1' refers to the first position away from the right hand end of the C-terminus of the cleavage site (ie. N-terminus


10 first position); whereas P1 starts the numbering from the left hand side of the C-terminus cleavage site, P2: second position from the C-terminus, etc.)(see Berger A. & Schechter I., Transactions of the Royal Society London series (1970), B257, 249-264].

15

As used herein the term "1-aminocyclopropyl-carboxylic acid" (Acca) refers to a compound of formula:



20 As used herein the term "*tert*-butylglycine" refers to a compound of the formula:



The term "residue" with reference to an amino acid or amino acid derivative

25 means a radical derived from the corresponding  $\alpha$ -amino acid by eliminating the hydroxyl of the carboxy group and one hydrogen of the  $\alpha$ -amino acid group. For


instance, the terms Gln, Ala, Gly, Ile, Arg, Asp, Phe, Ser, Leu, Cys, Asn, Sar and Tyr represent the "residues" of *L*-glutamine, *L*-alanine, glycine, *L*-isoleucine, *L*-arginine, *L*-aspartic acid, *L*-phenylalanine, *L*-serine, *L*-leucine, *L*-cysteine, *L*-asparagine, sarcosine and *L*-tyrosine, respectively.

5

The term "side chain" with reference to an amino acid or amino acid residue means a group attached to the  $\alpha$ -carbon atom of the  $\alpha$ -amino acid. For example, the R-group side chain for glycine is hydrogen, for alanine it is methyl, for valine it is isopropyl. For the specific R-groups or side chains of the  $\alpha$ -amino acids reference is made to A.L. Lehninger's text on Biochemistry (see chapter 4).

10

The compounds of the present invention have the structure of Formula I:



15

wherein:

- (a)  $R_1$  is Het or aryl;
- (b)  $m$  is 1 or 2;
- (c)  $n$  is 1 or 2;
- (d)  $R_2$  is H; or  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{3-7}$  cycloalkyl, each optionally substituted with halogen;
- (e)  $R_3$  is  $C_{1-8}$  alkyl optionally substituted with halo, cyano, amino,  $C_{1-6}$  dialkylamino,  $C_{6-10}$  aryl,  $C_{7-14}$  alkylaryl,  $C_{1-6}$  alkoxy, carboxy, hydroxy, aryloxy,  $C_{7-14}$  alkylaryloxy,  $C_{2-6}$  alkylester or  $C_{8-15}$  alkylarylester;  $C_{3-12}$  alkenyl,  $C_{3-7}$  cycloalkyl, or  $C_{4-10}$  alkylcycloalkyl, wherein the cycloalkyl or alkylcycloalkyl are optionally substituted

20


25


- with hydroxy, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl or C<sub>1-6</sub> alkoxy; or R<sub>3</sub> together with the carbon atom to which it is attached forms a C<sub>3-7</sub> cycloalkyl group optionally substituted with C<sub>2-6</sub> alkenyl;
- (f) Y is H, phenyl substituted with nitro, pyridyl substituted with nitro, or C<sub>1-6</sub> alkyl optionally substituted with cyano, OH or C<sub>3-7</sub> cycloalkyl; provided that if R<sub>4</sub> or R<sub>5</sub> is H then Y is H;
- (g) B is H, C<sub>1-6</sub> alkyl, R<sub>4</sub>-(C=O)-, R<sub>4</sub>O(C=O)-, R<sub>4</sub>-N(R<sub>5</sub>)-C(=O)-, R<sub>4</sub>-N(R<sub>5</sub>)-C(=S)-, R<sub>4</sub>SO<sub>2</sub>-, or R<sub>4</sub>-N(R<sub>5</sub>)-SO<sub>2</sub>-;
- (h) R<sub>4</sub> is (i) C<sub>1-10</sub> alkyl optionally substituted with phenyl, carboxyl, C<sub>1-6</sub> alkanoyl, 1-3 halogen, hydroxy, -OC(O)C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, amino optionally substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amido; (ii) C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkoxy, or C<sub>4-10</sub> alkylcycloalkyl, each optionally substituted with hydroxy, carboxyl, (C<sub>1-6</sub> alkoxy)carbonyl, amino optionally substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amido; (iii) C<sub>6-10</sub> aryl or C<sub>7-16</sub> arylalkyl, each optionally substituted with C<sub>1-6</sub> alkyl, halogen, nitro, hydroxy, amido, (lower alkyl) amido, or amino optionally substituted with C<sub>1-6</sub> alkyl; (iv) Het; (v) bicyclo(1.1.1)pentane; or (vi) -C(O)OC<sub>1-6</sub> alkyl, C<sub>2-6</sub>alkenyl or C<sub>2-6</sub> alkynyl;
- (i) R<sub>5</sub> is H; C<sub>1-6</sub> alkyl optionally substituted with 1-3 halogens; or C<sub>1-6</sub> alkoxy provided R<sub>4</sub> is C<sub>1-10</sub> alkyl;
- (j) X is O, S, SO, SO<sub>2</sub>, OCH<sub>2</sub>, CH<sub>2</sub>O or NH;
- (k) R' is Het, C<sub>6-10</sub> aryl or C<sub>7-14</sub> alkylaryl, each optionally substituted with R<sup>a</sup>; and
- (l) R<sup>a</sup> is C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-6</sub> alkoxy, C<sub>3-7</sub> cycloalkoxy, halo-C<sub>1-6</sub> alkyl, CF<sub>3</sub>, mono- or di- halo-C<sub>1-6</sub> alkoxy, cyano, halo, thioalkyl, hydroxy, alkanoyl, NO<sub>2</sub>, SH, , amino, C<sub>1-6</sub> alkylamino, di (C<sub>1-6</sub>) alkylamino, di (C<sub>1-6</sub>) alkylamide, carboxyl, (C<sub>1-6</sub>) carboxyester, C<sub>1-6</sub> alkylsulfone, C<sub>1-6</sub> alkylsulfonamide, di (C<sub>1-6</sub>) alkyl(alkoxy)amine, C<sub>6-10</sub> aryl, C<sub>7-14</sub> alkylaryl, or a 5-7 membered monocyclic heterocycle;

or a pharmaceutically acceptable enantiomer, diastereomer, salt, solvate or prodrug thereof.

Preferably, Het is unsubstituted Het or Het substituted with from one to three of halo, cyano, trifluoromethyl, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, amido, C<sub>1-6</sub> alkanoylamino, amino, phenyl or phenylthio, said phenyl or phenyl portion of  
5 phenylthio being unsubstituted or substituted with one to three substituents selected from halo, cyano, nitro, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, amido or phenyl;

More preferably, R<sub>1</sub> is selected from the group consisting of





- 5 In another aspect of the invention,  $R_1$  is a monocyclic aryl, preferably a  $C_6$  aryl, optionally substituted with halo, e.g., chloro, hydroxyl,  $C_{1-6}$  alkoxy, e.g., methoxy, or halo $C_{1-6}$  alkoxy, e.g., trifluoromethoxy.

Preferably, R<sub>2</sub> is C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl or C<sub>3-7</sub> cycloalkyl. More preferably, R<sub>2</sub> is C<sub>2-6</sub> alkenyl. Preferably, R<sub>3</sub> is C<sub>1-8</sub> alkyl optionally substituted with C<sub>6</sub>aryl, C<sub>1-6</sub> alkoxy, carboxy, hydroxy, aryloxy, C<sub>7-14</sub> alkylaryloxy, C<sub>2-6</sub> alkylester or C<sub>8-15</sub> alkylarylester; C<sub>3-12</sub> alkenyl; C<sub>3-7</sub> cycloalkyl; or C<sub>4-10</sub> alkylcycloalkyl. More  
5 preferably, R<sub>3</sub> is C<sub>1-8</sub> alkyl optionally substituted with C<sub>1-6</sub> alkoxy; or C<sub>3-7</sub> cycloalkyl.


Preferably, Y is H. Preferably, B is H, C<sub>1-6</sub> alkyl, R<sub>4</sub>-(C=O)-, R<sub>4</sub>O(C=O)-, R<sub>4</sub>-N(R<sub>5</sub>)-C(=O)-, R<sub>4</sub>-N(R<sub>5</sub>)-C(=S)-, R<sub>4</sub>SO<sub>2</sub>-, or R<sub>4</sub>-N(R<sub>5</sub>)-SO<sub>2</sub>-. More preferably, B is R<sub>4</sub>-(C=O)-, R<sub>4</sub>O(C=O)-, or R<sub>4</sub>-N(R<sub>5</sub>)-C(=O)-. Even more preferably, B is  
10 R<sub>4</sub>O(C=O)- and R<sub>4</sub> is C<sub>1-6</sub> alkyl. Preferably, R<sub>4</sub> is (i) C<sub>1-10</sub> alkyl optionally substituted with phenyl, carboxyl, C<sub>1-6</sub> alkanoyl, 1-3 halogen, hydroxy, C<sub>1-6</sub> alkoxy; (ii) C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkoxy, or C<sub>4-10</sub> alkylcycloalkyl; or (iii) C<sub>6-10</sub> aryl or C<sub>7-16</sub> arylalkyl, each optionally substituted with C<sub>1-6</sub> alkyl or halogen. More preferably, R<sub>4</sub> is (i) C<sub>1-10</sub> alkyl optionally substituted with 1-3 halogen or C<sub>1-6</sub> alkoxy; or (ii) C<sub>3-7</sub>  
15 cycloalkyl or C<sub>4-10</sub> alkylcycloalkyl. Preferably, R<sub>5</sub> is H or C<sub>1-6</sub> alkyl optionally substituted with 1-3 halogens. More preferably, R<sub>5</sub> is H.

Preferably, X is O or NH. Preferably, R' is Het or C<sub>6-10</sub> aryl each optionally substituted with R<sup>a</sup>. More preferably, R' is Het. Preferably, the heterocycle contains  
20 1 or 2 nitrogen atoms and optionally a sulfur atom or an oxygen atom in the ring. More preferably, the heterocycle is substituted with at least one of C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, halo, C<sub>6-10</sub> aryl, C<sub>7-14</sub> alkylaryl, or a 5-7 membered monocyclic heterocycle. Preferably, R<sup>a</sup> is C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-6</sub> alkoxy, halo-C<sub>1-6</sub> alkyl, halo, amino, C<sub>6</sub> aryl, or a 5-7 membered monocyclic heterocycle.

25

The substituents from each grouping may be selected individually and combined in any combination which provides a stable compound in accordance with the present invention. Also, more than one substituent from each group may be substituted on the core group provided there are sufficient available binding sites.  
30 For example, each of the following R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> or R<sub>9</sub> substituents, C<sub>1-6</sub> alkoxy, C<sub>6</sub> aryl and a 5-7 membered monocyclic heterocycle, may be substituted on a bicyclic heterocycle.

In a preferred aspect, the compounds of the present invention have the structure of Formula II:



5

wherein:

- (a)  $R_1$  is unsubstituted Het or Het substituted with from one to three of halo, cyano, trifluoromethyl,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amido,  $C_{1-6}$  amino, phenyl, said phenyl being unsubstituted or substituted with one to three substituents selected from halo, cyano, nitro,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amido or phenyl; or  $C_6$  aryl;
- (b)  $R_2$  is  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{3-7}$  cycloalkyl;
- (c)  $R_3$  is  $C_{1-8}$  alkyl optionally substituted with  $C_6$  aryl,  $C_{1-6}$  alkoxy, carboxy, hydroxy, aryloxy,  $C_{7-14}$  alkylaryloxy,  $C_{2-6}$  alkylester,  $C_{8-15}$  alkylarylester;  $C_{3-12}$  alkenyl,  $C_{3-7}$  cycloalkyl, or  $C_{4-10}$  alkylcycloalkyl;
- (d) B is H,  $C_{1-6}$  alkyl,  $R_4-(C=O)-$ ,  $R_4O(C=O)-$ ,  $R_4-N(R_5)-C(=O)-$ ,  $R_4-N(R_5)-C(=S)-$ ,  $R_4SO_2-$ , or  $R_4-N(R_5)-SO_2-$ ;
- (e)  $R_4$  is (i)  $C_{1-10}$  alkyl optionally substituted with phenyl, carboxyl,  $C_{1-6}$  alkanoyl, 1-3 halogen, hydroxy,  $C_{1-6}$  alkoxy; (ii)  $C_{3-7}$  cycloalkyl,  $C_{3-7}$  cycloalkoxy, or  $C_{4-10}$  alkylcycloalkyl; or (iii)  $C_{6-10}$  aryl or  $C_{7-16}$  arylalkyl, each optionally substituted with  $C_{1-6}$  alkyl or halogen;
- (f)  $R_5$  is H or  $C_{1-6}$  alkyl optionally substituted with 1-3 halogens;
- (g) X is O or NH;
- (h)  $R'$  is Het; or  $C_{6-10}$  aryl optionally substituted with  $R^a$ ; and
- (i)  $R^a$  is  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl,  $C_{1-6}$  alkoxy, halo- $C_{1-6}$  alkyl, halo, amino,  $C_6$  aryl, or a 5-7 membered monocyclic heterocycle;

25


or a pharmaceutically acceptable enantiomer, diastereomer, salt, solvate or prodrug thereof.

5 In one aspect of the invention, R' is a bicyclic heterocycle. Preferably, the heterocycle contains 1 or 2 nitrogen atoms and optionally a sulfur atom or an oxygen atom in the ring. More preferably, the heterocycle is substituted with at least one of C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, halo, C<sub>6</sub> aryl, and a 5-7 membered monocyclic heterocycle. Even more preferably, R' is a bicyclic heterocycle containing 1 nitrogen atom and  
10 substituted with methoxy and at least one of a C<sub>6</sub> aryl and a 5-7 membered monocyclic heterocycle.

In another aspect of the invention, R' is a monocyclic heterocycle. Preferably, the heterocycle contains 1 or 2 nitrogen atoms and optionally a sulfur atom or an oxygen atom in the ring. More preferably, the heterocycle is substituted  
15 with at least one of C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, halo, C<sub>6-10</sub> aryl, C<sub>7-14</sub> alkylaryl, or a 5-7 membered monocyclic heterocycle. Even more preferably, R' is a monocyclic heterocycle containing 1 or 2 nitrogen atoms and substituted with methoxy and at least one of a C<sub>6</sub> aryl and a 5-7 membered monocyclic heterocycle.

20

In a more preferred aspect of the invention, the compounds have the structure of Formula III



(III)

25

wherein:

- (a) R<sub>1</sub> is unsubstituted Het or Het substituted with one to three of halo, cyano, trifluoromethyl, C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, amido, or amino; or a C<sub>6</sub> aryl;
- 5 (b) R<sub>2</sub> is C<sub>2-6</sub> alkenyl;
- (c) R<sub>3</sub> is C<sub>1-8</sub> alkyl;
- (d) B is R<sub>4</sub>O(C=O)-, or R<sub>4</sub>-N(H)-C(=O)-;
- (e) R<sub>4</sub> is C<sub>1-10</sub> alkyl;
- (f) R' is a bicyclic heterocycle optionally substituted with R<sup>a</sup>; and
- 10 (g) R<sup>a</sup> is C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, halo, C<sub>6</sub> aryl, or a 5-7 membered monocyclic heterocycle;

or a pharmaceutically acceptable enantiomer, diastereomer, salt, solvate or prodrug thereof.

15

Preferably, R<sub>2</sub> is vinyl, R<sub>3</sub> is t-butyl, R<sub>4</sub> is t-butyl, R' is quinoline or isoquinoline optionally substituted with R<sup>a</sup>. Preferably, R<sup>a</sup> is C<sub>1-6</sub> alkoxy. More preferably, R<sup>a</sup> further includes at least one of C<sub>6</sub> aryl or a 5-7 membered monocyclic heterocycle.

20

The compounds of the present invention can be manufactured by methods known to those skilled in the art, see e.p., US Patent No. 6,323,180 and US Patent Appl. 20020111313 A1. The following methods set forth below are provided for illustrative purposes and are not intended to limit the scope of the claimed invention.

25

It will be recognized that it may be preferred or necessary to prepare such a compound in which a functional group is protected using a conventional protecting group then to remove the protecting group to provide a compound of the present invention. The details concerning the use of protecting groups in accordance with the present invention are known to those skilled in the art.

30

The compounds of the present invention may, for example, be synthesized according to a general process as illustrated in Scheme I (wherein CPG is a carboxyl protecting group and APG is an amino protecting group):



carbonyldiimidazole method, phosphorus reagents or oxidation-reduction methods. Some of these methods (especially the carbodiimide method) can be enhanced by adding 1-hydroxybenzotriazole or 4-DMAP. These coupling reactions can be performed in either solution (liquid phase) or solid phase.

5

More explicitly, the coupling step involves the dehydrative coupling of a free carboxyl of one reactant with the free amino group of the other reactant in the present of a coupling agent to form a linking amide bond. Descriptions of such coupling agents are found in general textbooks on peptide chemistry, for example, M. Bodanszky, "Peptide Chemistry", 2<sup>nd</sup> rev ed., Springer-Verlag, Berlin, Germany, (1993). Examples of suitable coupling agents are N,N'-dicyclohexylcarbodiimide, 1-hydroxybenzotriazole in the presence of N,N'-dicyclohexylcarbodiimide or N-ethyl-N'-[(3-dimethylamino)propyl]carbodiimide. A practical and useful coupling agent is the commercially available (benzotriazol-1-yloxy)tris-(dimethylamino)phosphonium hexafluorophosphate, either by itself or in the present of 1-hydroxybenzotriazole or 4-DMAP. Another practical and useful coupling agent is commercially available 2-(1H-benzotriazol-1-yl)-N, N, N', N'-tetramethyluronium tetrafluoroborate. Still another practical and useful coupling agent is commercially available O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate. The coupling reaction is conducted in an inert solvent, e.g. dichloromethane, acetonitrile or dimethylformamide. An excess of a tertiary amine, e.g. diisopropylethylamine, N-methylmorpholine, N-methylpyrrolidine or 4-DMAP is added to maintain the reaction mixture at a pH of about 8. The reaction temperature usually ranges between 0 °C and 50 °C and the reaction time usually ranges between 15 min and 24 h.

The functional groups of the constituent amino acids generally must be protected during the coupling reactions to avoid formation of undesired bonds. Protecting groups that can be used are listed, for example, in Greene, "Protective Groups in Organic Chemistry", John Wiley & Sons, New York (1981) and "The Peptides: Analysis, Synthesis, Biology", Vol. 3, Academic Press, New York (1981), the disclosures of which are hereby incorporated by reference.

The  $\alpha$ -amino group of each amino acid to be coupled to the growing peptide chain must be protected (APG). Any protecting group known in the art can be used. Examples of such groups include: 1) acyl groups such as formyl, trifluoroacetyl, phthalyl, and *p*-toluenesulfonyl; 2) aromatic carbamate groups such as benzyloxycarbonyl (Cbz or Z) and substituted benzyloxycarbonyls, and 9-fluorenylmethyloxycarbonyl (Fmoc); 3) aliphatic carbamate groups such as tert-butyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; 4) cyclic alkyl carbamate groups such as cyclopentylloxycarbonyl and adamantylloxycarbonyl; 5) alkyl groups such as triphenylmethyl and benzyl; 6)trialkylsilyl such as trimethylsilyl; and 7) thiol containing groups such as phenylthiocarbonyl and dithiasuccinoyl.

The preferred  $\alpha$ -amino protecting group is either Boc or Fmoc. Many amino acid derivatives suitably protected for peptide synthesis are commercially available.

The  $\alpha$ -amino protecting group of the newly added amino acid residue is cleaved prior to the coupling of the next amino acid. When the Boc group is used, the methods of choice are trifluoroacetic acid, neat or in dichloromethane, or HCl in dioxane or in ethyl acetate. The resulting ammonium salt is then neutralized either prior to the coupling or in situ with basic solutions such as aqueous buffers, or tertiary amines in dichloromethane or acetonitrile or dimethylformamide. When the Fmoc group is used, the reagents of choice are piperidine or substituted piperidine in dimethylformamide, but any secondary amine can be used. The deprotection is carried out at a temperature between 0°C and room temperature (rt or RT) usually 20-22°C.

25

Any of the amino acids having side chain functionalities must be protected during the preparation of the peptide using any of the above-described groups. Those skilled in the art will appreciate that the selection and use of appropriate protecting groups for these side chain functionalities depend upon the amino acid and presence of other protecting groups in the peptide. The selection of such protecting groups is important in that the group must not be removed during the deprotection and coupling of the  $\alpha$ -amino group.

For example, when Boc is used as the  $\alpha$ -amino protecting group, the following side chain protecting groups are suitable: *p*-toluenesulfonyl (tosyl) moieties can be used to protect the amino side chain of amino acids such as Lys and Arg; acetamidomethyl, benzyl (Bn), or *tert*-butylsulfonyl moieties can be used to protect the sulfide containing side chain of cysteine; benzyl (Bn) ethers can be used to protect the hydroxy containing side chains of serine, threonine or hydroxyproline; and benzyl esters can be used to protect the carboxy containing side chains of aspartic acid and glutamic acid.

10

When Fmoc is chosen for the  $\alpha$ -amine protection, usually *tert*-butyl based protecting groups are acceptable. For instance, Boc can be used for lysine and arginine, *tert*-butyl ether for serine, threonine and hydroxyproline, and *tert*-butyl ester for aspartic acid and glutamic acid. Triphenylmethyl (Trityl) moiety can be used to protect the sulfide containing side chain of cysteine.

15


Once the elongation of the peptide is completed all of the protecting groups are removed. When a liquid phase synthesis is used, the protecting groups are removed in whatever manner is dictated by the choice of protecting groups. These procedures are well known to those skilled in the art.

20

Further, the following guidance may be followed in the preparation of compounds of the present invention. For example, to form a compound where  $R_4-C(O)-$ ,  $R_4-S(O)_2-$ , a protected P3 or the whole peptide or a peptide segment is coupled to an appropriate acyl chloride or sulfonyl chloride respectively, that is either commercially available or for which the synthesis is well known in the art. In preparing a compound where  $R_4O-C(O)-$ , a protected P3 or the whole peptide or a peptide segment is coupled to an appropriate chloroformate that is either commercially available or for which the synthesis is well known in the art. For Boc-derivatives  $(Boc)_2O$  is used.

30

For example:



Cyclopentanol is treated with phosgene to furnish the corresponding chloroformate.

5

The chloroformate is treated with the desired  $\text{NH}_2$ -tripeptide in the presence of a base such as triethylamine to afford the cyclopentylcarbamate.

In preparing a compound where  $\text{R}_4\text{-N(R}_5\text{)-C(O)-}$ , or  $\text{R}_4\text{-NH-C(S)-}$ , a protected P3 or the whole peptide or a peptide segment is treated with phosgene followed by amine as described in SynLett. Feb 1995; (2); 142-144 or is reacted with the commercially available isocyanate and a suitable base such as triethylamine.

In preparing a compound where  $\text{R}_4\text{-N(R}_5\text{)-S(O}_2\text{)}$ , a protected P3 or the whole peptide or a peptide segment is treated with either a freshly prepared or commercially available sulfamyl chloride followed by amine as described in patent Ger. Offen.(1998), 84 pp. DE 19802350 or WO 98/32748.


The  $\alpha$ -carboxyl group of the C-terminal residue is usually protected as an ester (CPG) that can be cleaved to give the carboxylic acid. Protecting groups that can be used include: 1) alkyl esters such as methyl, trimethylsilylethyl and t-butyl, 2) aralkyl esters such as benzyl and substituted benzyl, or 3) esters that can be cleaved by mild base treatment or mild reductive means such as trichloroethyl and phenacyl esters.

The resulting  $\alpha$ -carboxylic acid (resulting from cleavage by mild acid, mild base treatment or mild reductive means) is coupled with a  $\text{R}_1\text{SO}_2\text{NH}_2$ .

Compounds of the present invention can be prepared by many methods including those described in the examples, below, and as described in U.S. Patent No. 6,323,180 and U.S. Patent Application No. 10/001,850 filed on November 20, 2001. The teachings of U.S. Patent No. 6,323,180 and U.S. Patent Application No. 10/001,850 are incorporated herein, in their entirety, by reference.


Scheme II further shows the general process wherein compounds of Formula I are constructed by the coupling of tripeptide carboxylic acid intermediate (1) with a P1' sulfonamide. (It should be noted that the groups R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub> as shown below represent substituents of the heterocyclic system.) Said coupling reaction requires treatment of carboxylic acid (1) with a coupling reagent such as carbonyl diimidazole in a solvent such as THF, which can be heated to reflux, followed by the addition of the formed derivative of (1), to the P1' sulfonamide, in a solvent such as THF or methylene chloride in the presence of a base such as DBU.

### Scheme II





An alternative process for the construction of compounds of Formula I is shown in Scheme III. Therein the P1' sulfonamide element is coupled to the P1 element using the process employed in Scheme 1. The resulting P1-P1' moiety can then be deprotected at it's amino terminus. In this general example a Boc protecting group is employed but one skilled in the art would recognize that a number of suitable amino protecting groups could be employed in this process. Said Boc protecting group can be removed using acid such as trifluoroacetic acid in a solvent such as dichloroethane to provide the deprotected amine as the TFA salt. Said TFA amine salt can be directly employed in the subsequent coupling reaction or as an alternative the TFA

amine salt can be first converted to the HCl amine salt, and this HCl amine salt is used in said coupling reaction as shown in Scheme III. The coupling of said HCl amine salt (3) with the carboxyl terminus a P4-P3-P2 intermediate can be achieved using coupling reagents, such as HATU, in solvents such as dichloromethane to provide compounds of Formula I (4).




An alternative process for the construction of compounds of Formula I is shown in Scheme IV. Herein the hydrochloride salt of the P1-P1' terminal amine (1) is coupled to the free carboxyl group of the P2 element using coupling agents such as PyBOP, in the presence of a base such as diisopropyl amine, and in a solvent such as methylene chloride. The resulting P2-P1-P1' intermediate can be converted to compounds of Formula I in a two step process wherein the first step is deprotection of the P2 amine terminus using an acid such as TFA in a solvent such as methylene chloride. The resulting trifluoroacetic acid salt can be coupled with the carboxyl terminus of the P4-P3 element using standard coupling agents such as PyBop in the presence of base such as diisopropyl amine, and using solvents such methylene chloride to provide compounds of Formula I (4).

**Scheme IV**

The P4-P3-P2 intermediate utilized in the above schemes can be constructed as previously described with a further description of this process shown in general

5 Scheme V. Therein the free carboxyl terminus of the P4-P3 intermediate (1), can be coupled to the amino terminus of the P2 element to provide the P4-P3-P2 dipeptide (2). The carboxyl terminus of the P4-P3-P2 intermediate can be deprotected by saponification of the ester group to provide P4-P3-P2 as the free carboxylic acid (3).

10 Intermediates like (3) can be converted to compounds of Formula I using the methods described herein.

**Scheme V**


Compounds of Formula 1 can also be converted into other compounds of Formula I as described herein. An example of such a process is shown in Scheme VI wherein a compound of Formula I (1) which bears a Boc group at the P4 position is converted in a compound of Formula I (3) wherein said compound bears a urea group at the P4 position.

5 The conversion of (1) to (3) can be carried out in a two step process the first of which is the conversion of (1) to amine (2) by treatment of (1) with an acid such as TFA in a solvent such as methylene chloride. The resulting amine TFA salt can be treated with an isocyanate in the presence of one equivalent of base to provide a compound of Formula I (3) wherein the P3 moiety is capped with a urea. As

10 previously noted one skilled in the art will recognize that intermediate (2) can be used as starting materials for the preparation of compounds of Formula I wherein the P3 group is capped with an amide or a sulfonamide, or thiourea, or a sulfamide. The construction of said compounds of Formula I can be achieved using standard conditions for the formation of said P4 functionalities from amines.

### Scheme VI

Process P4-P3-P2-P1-P1'  $\longrightarrow$  P3-P2-P1-P1'  $\longrightarrow$  P4-P3-P2-P1-P1'



15


In the construction of compounds of Formula I, the P1' terminus is incorporated into the molecules using one of the general processes outlined above and described in more detail below. In some examples the P1' elements, that is the

heterocyclesulfonamides are commercially available or can be prepared as described herein.


The P1 elements utilized in generating compounds of Formula I are in some cases  
5 commercially available, but are otherwise synthesized using the methods described herein and subsequently incorporated into compounds of Formula I using the methods described herein. The substituted P1 cyclopropylamino acids can be synthesized following the general process outline in Scheme VIII.

10 Treatment of commercially available or easily synthesized imine (1) with 1,4-dihalobutene (2) in presence of a base produces, provides the resulting imine (3). Acid hydrolysis of 3 then provides 4, which has an allyl substituent syn to the carboxyl group as a major product. The amine moiety of 4 can be protected using a Boc group to provide the fully protected amino acid 5. This intermediate is a racemate  
15 which can be resolved by an enzymatic process wherein the ester moiety of 5 is cleaved by a protease to provide the corresponding carboxylic acid. Without being bound to any particular theory, it is believed that this reaction is selective in that one of the enantiomers undergoes the reaction at a much greater rate than its mirror image providing for a kinetic resolution of the intermediate racemate. In the examples cited  
20 herein, the more preferred stereoisomer for integration into compounds of Formula I is 5a which houses the (1R, 2S) stereochemistry. In the presence of the enzyme, this enantiomer does not undergo ester cleavage and thereby this enantiomer 5a is recovered from the reaction mixture. However, the less preferred enantiomer, 5b with houses the (1S, 2R) stereochemistry undergoes ester cleavage, i.e., hydrolysis, to  
25 provide the free acid 6. Upon completion of this reaction, the ester 5a can be separated from the acid product 6 by routine methods such as, for example, aqueous extraction methods or chromatography.


## Scheme VIII



- Procedures for making P2 intermediates and compounds of Formula I are shown in the Schemes below. It should be noted that in many cases reactions are depicted for only one position of an intermediate. However, it is to be understood that such reactions could be used to impart modifications to other positions within this intermediate. Moreover, said intermediates, reaction conditions and methods given in the specific examples are broadly applicable to compounds with other substitution patterns. The general Schemes outlined below are followed with examples herein.
- Both general and specific examples are non-limiting, as for example the isoquinoline nucleus is shown as part of the general scheme, Scheme IX, however, this pathway represents a viable process for the construction of alternate heterocycle substituents as replacements for the isoquinoline element, such as quinolines, or pyridines.




Scheme IX shows the coupling of an N-protected C4-hydroxyproline moiety with a heterocycle to form intermediate (4) and the subsequent modification of said intermediate (4) to a compound of Formula I by the process of peptide elongation as described herein. It should be noted that in the first step, that is the coupling of the C4-hydroxy proline group with the heteroaryl element, a base is employed. One skilled in the art would recognized that this coupling can be done using bases such as potassium tert-butoxide, or sodium hydride, in solvent such as DMF or DMSO or THF. This coupling to the isoquinoline ring system occurs at the C1 position (numbering for isoquinoline ring system shown in intermediate 2 of Scheme IX) and is directed by the chloro group which is displaced in this process. It should be noted that the alternative leaving groups can be utilized at this position such as a fluoro as shown in the Scheme. Said fluoro intermediates (3) are available from the corresponding chloro compound using literature procedures described herein. It should also be noted that the position of the leaving group (chloro or fluoro) in a given ring system can vary as shown in Scheme X, wherein the leaving group (fluoro in this example) is in the C6 position of the isoquinoline ring system of intermediate (2).



It should be further noted that the position of the ring heteroatom(s) in intermediates like (2) of Scheme IX and Scheme X is also variable, as defined by the term heterocycle described herein. In Scheme X intermediate (2) can be coupled to a C4 hydroxy proline derivative to provide the P2 element (3). This C6-substituted isoquinoline derivative can be converted to compounds of Formula I using the methods described herein.

An alternative to the method described above for the coupling of the C4-hydroxyproline to aromatics and heteroaromatics, is provided in the Mitsunobu reaction as depicted in

### Scheme XI




step 1 of Scheme XI. In this general reaction Scheme a C4-hydroxy proline derivative is coupled to a quinazoline ring system. This reaction makes use of reagents such as triphenylphosphine and DEAD (diethylazodicarboxylate) in aprotic solvents such as THF or dioxane and can be used for the formation of aryl and heteroaryl ethers. Note that in the course of this coupling reaction the stereochemistry of the C4 chiral center in the C4-hydroxyproline derivative is inverted and thereby it is necessary to use the C4-hydroxyproline derivative housing the (S) stereochemistry at the C4 position as starting material. (as shown in Scheme XI). It should be noted that numerous modifications and improvements of the Mitsunobu reaction have been described in the literature, the teachings of which are incorporated herein.

In a subset of examples herein, isoquinolines are incorporated into the final compounds and specifically into the P2 region of said compounds. One skilled in the

art would recognize that a number of general methods are available for the synthesis of isoquinolines. Moreover, said isoquinolines generated by these methods can be readily incorporated into final compounds of Formula I using the processes described herein. One general methodology for the synthesis of isoquinolines is shown in

5 Scheme XII, wherein cinnamic acid derivatives, shown in general form as structure (2) are

**Scheme XII**



Reference: N. Briet et al, Tetrahedron, 2002, 5761

converted to 1-chloroisoquinolines in a four step process. Said chloroisoquinolines can be subsequently used in coupling reactions to C4-hydroxyproline derivatives as

10 described herein. The conversion of cinnamic acids to chloroquinolines begins with the treatment of cinnamic acid with an alkylchloroformate in the presence of a base. The resulting anhydride is then treated with sodium azide which results in the formation of an acylazide (3) as shown in the Scheme. Alternate methods are available for the formation of acylazides from carboxylic acids as for example said


15 carboxylic acid can be treated with diphenylphosphorylazide (DPPA) in an aprotic solvent such as methylene chloride in the presence of a base. In the next step of the reaction sequence the acylazide (3) is converted to the corresponding isoquinolone (4) as shown in the Scheme. In the event the acylazide is heated to a temperature of approximately 190 degrees celcius in a high boiling solvent such a diphenylmethane.

20 This reaction is general and provides moderate to good yields of substituted isoquinolone from the corresponding cinnamic acid derivatives. It should be noted that said cinnamic acid derivatives are available commercially or can be obtained from the corresponding benzaldehyde (1) derivative by direct condensation with malonic acid or derivatives thereof and also by employing a Wittig reaction. The intermediate

isoquinolones (4) of Scheme XII can be converted to the corresponding 1-chloroisoquinoline by treatment with phosphorous oxychloride. This reaction is general and can be applied to any of the isoquinolones, quinolones or additional heterocycles as shown herein to convert a hydroxy substituent to the corresponding chloro compound when said hydroxy is in conjugation with a nitrogen atom in said heterocyclic ring systems.

An alternative method for the synthesis of the isoquinoline ring system is the Pomeranz-Fritsch procedure. This general method is outlined in Scheme XIII. The process begins with the conversion of a benzaldehyde derivative (1) to a functionalized imine (2). Said imine is then converted to the isoquinoline ring system by treatment with acid at elevated

Scheme XIII




Pomeranz-Fritsch synthesis

K. Hirao, R. Tsuchiya, Y. Yano, H. Tsue, *Heterocycles* 42(1) 1996, 415-422

temperature. This isoquinoline synthesis of Scheme XIII is general, and it should be noted that this process is particularly useful in procuring isoquinoline intermediates that are substituted at the C8 position (note: in intermediate (3) of Scheme XIII the C8 position of the isoquinoline ring is substituted with substituent R<sub>11</sub>). The intermediate isoquinolines (3) can be converted to the corresponding 1-chloroquinolines (5) in a two step process as shown. The first step in this sequence is the formation of the isoquinoline N-oxide(4) by treatment of isoquinoline (3) with meta-chloroperbenzoic acid in an aprotic solvent such as dichloromethane. Intermediate (4) can be converted to the corresponding 1-chloroquinoline by treatment with phosphorous oxychloride in refluxing chloroform. Note this two step process is general and can be employed to procure chloroisoquinolines and chloroquinolines from the corresponding isoquinolines and quinolines respectively.

Another method for the synthesis of the isoquinoline ring system is shown in Scheme XIV. In this process an ortho-alkylbenzamide derivative (1) is treated with a strong


#### Scheme XIV



5 base such as tert-butyl lithium in a solvent such as THF at low temperature. To this reaction mixture is then added a nitrile derivative, which undergoes an addition reaction with the anion derived from deprotonation of (1), resulting in the formation of (2). This reaction is general and can be used for the formation of substituted isoquinolines. Intermediate (2) of Scheme XIV can be converted to the corresponding  
10 1-chloroquinoline by the methods described herein.


An additional method for the synthesis of isoquinolines is shown in Scheme XV. The deprotonation of intermediate (1) using tert-butyl lithium is described above. In the present method however, said intermediate anion is trapped by an ester, resulting in the formation of intermediate (2) as shown below. In a subsequent reaction ketone  
15 (2) is condensed with ammonium acetate at elevated temperature providing for the formation of quinolone (3). This reaction is general and can be applied for the construction of substituted isoquinolones which can then be converted to the corresponding 1-chloroisoquinolines as described herein.

#### Scheme XV



20


Yet an additional method for the construction of isoquinolines is found in Scheme XVI. In the first step of this process an ortho-alkylarylimine derivatives such as (1) is subjected to deprotonation conditions (sec-butyl lithium, THF) and the resulting anion is quenched by

**Scheme XVI**

L. Flippin, J. Muchowski, JOC, 1993, 2631-2632

the addition of an activated carboxylic acid derivative such as a Weinreb amide. The resulting keto imine (2) can be converted to the corresponding isoquinoline by condensation with ammonium acetate at elevated temperatures. This method is  
 5 general and can be used for the synthesis of substituted isoquinolines. Said isoquinolines can be converted to the corresponding 1-chloroquinoline by the methods described herein.

The heterocycles described herein, and which are incorporated into the compounds of Formula I can be further functionalized. It is obvious to one skilled in the art that  
 10 additional functionalization of said heterocycles can be done either before or after incorporation of these functionalities into compounds of Formula I. The following Schemes illustrate this point. For example Scheme XVII shows the conversion of a 1-chloro-

**Scheme XVII**


15 6-fluoro-isoquinoline to the corresponding 1-chloro-6-alkoxy-isoquinoline species, by treatment of (1) of (eq.1) with a sodium or potassium alkoxide species in the alcohol solvent from which the alkoxide is derived at room temperature. In some cases it may be necessary to heat the reaction to drive it to completion. Said

chloroquinoline can be incorporated into a compound of Formula I using the art described herein. Modifications of a P2 heterocyclic element can also be done after it's incorporation into compounds of Formula I as shown in (eq.2) of Scheme VXII. Specifically compounds such as (1) in (eq. 2) which contain a leaving group in the pthalazine nucleus can be displaced by a nucleophile such as an alkoxide in solvents such as the corresponding alcohol from which the alkoxide is derived. These reaction can be conducted at room temperature but in some cases it may be necessary to heat the reaction to drive it to completion.

10 Scheme XVIII provides a general example for the modification of heterocycles as defined herein by employing palladium mediated coupling reactions. Said couplings can be employed to functionalize a heterocycle at each position of the ring system providing said ring is suitably activated or functionalized, as for example with a chloride as shown in the Scheme. This sequence begins with 1-chloroisoquinoline (1) which upon treatment with metachloroperbenzoic acid can be converted to the corresponding N-oxide (2). Said intermediate (2) can be converted to the corresponding 1,3-dichloroisoquinoline (3) by treatment with phosphorous oxychloride in refluxing chloroform. Intermediate (3) can be coupled with N-Boc-4-hydroxyproline by the methods described herein to provide intermediate (5) as shown in the Scheme. Intermediate (5) can undergo a Suzuki coupling with an aryl boronic acid, in the presence of a palladium reagent and base, and in a solvent such as THF or toluene or DMF to provide the C3-arylisoquinoline intermediate (6). Heteroarylboronic acids can also be employed in this Pd mediated coupling process to provide C3-heteroarylisoquinolines. Intermediate (6) can be converted into final compounds of Formula I by the methods described herein.

15  
20  
25

## Scheme XVIII




Palladium mediated couplings of heteroaryl systems with aryl or heteroaryl elements can also be employed at a later synthetic stage in the construction of compounds of


5 Formula I as shown in Scheme IXX. Therein tripeptide acylsulfonamide intermediate (1) is coupled to a 1-chloro-3-bromoisoquinoline (2) using the previously described process of alkoxide displacement of an heteroarylhalo moiety to provide intermediate (3). The coupling of (1) and (2) is most efficient in the presence of a catalyst such as lanthanum chloride as described herein. The isoquinoline ring

10 system of intermediate (3) can be further functionalized by employing either Suzuki couplings (Process 1: subjecting (3) to heteroaryl or aryl boronic acids in the presence of a palladium catalyst such as palladium tetra(triphenylphosphine) and a base such as cesium carbonate in solvents such as DMF) or Stille couplings (Process

15 2: subjecting (3) to heteraryl or aryl tin derivatives in the presence of palladium catalyst such as palladium tetra(triphenylphosphine) in solvents such as toluene).




Palladium reactions can also be employed to couple C4-amino proline elements with functionalized heterocycles. Scheme XX shows intermediate (1) coupling with a functionalized isoquinoline in the presence of a palladium catalyst and a base in a solvent such as toluene. Intermediates like (3) can be converted to compounds of Formula I using the methods described herein.



The construction of functionalized isoquinoline ring systems is also possible employing [4+2] cycloaddition reactions. For example (Scheme XXI) the use of vinyl isocyanates (1) in cycloaddition reactions with benzyne precursors (2) provides functionalized isoquinolones (3). Said isoquinolones can be incorporated into compounds of Formula I using the methods described herein.

## Scheme XXI



Compounds of the invention can also be prepared by utilizing methods  
 5 known to those skilled in the art, such as, for example, the methods described in  
 patent application WO 03/099274, published December 3, 2003, and WO 03/099316,  
 published December 4, 2003.

The present invention also provides compositions comprising a compound of  
 10 the present invention, or a pharmaceutically acceptable enantiomer, diastereomer,  
 salt, solvate or prodrug thereof, and a pharmaceutically acceptable carrier.  
 Pharmaceutical compositions of the present invention comprise a therapeutically  
 effective amount of a compound of the invention, or a pharmaceutically acceptable  
 enantiomer, diastereomer, salt, solvate or prodrug thereof, and a pharmaceutically  
 15 acceptable carrier, with a pharmaceutically acceptable carrier, e.g., excipient, or  
 vehicle diluent.

The active ingredient, i.e., compound, in such compositions typically  
 comprises from 0.1 weight percent to 99.9 percent by weight of the composition, and  
 20 often comprises from about 5 to 95 weight percent.

Thus, in one aspect of the invention, there is provided a composition  
 comprising the compound of formula 1 and a pharmaceutically acceptable carrier.  
 Preferably, the composition further comprises a compound having anti-HCV activity.  
 25 As used herein, the term "anti-HCV activity" means the compound is effective to  
 inhibit the function of a target selected from the group consisting of HCV  
 metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B  
 protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH and a

nucleoside analog for the treatment of an HCV infection. Often, the other compound having anti-HCV activity is effective to inhibit the function of target in the HCV life cycle other than the HCV NS3 protease protein.

5           In one preferred aspect, the compound having anti-HCV activity is an interferon. Preferably, the interferon is selected from the group consisting of interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, lymphoblastiod interferon tau.

10           In another aspect of the invention, the compound having anti-HCV activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.

15           In one preferred aspect of the invention, the composition comprises a compound of the invention, an interferon and ribavirin.

20           In another preferred aspect of the invention, the compound having anti-HCV activity is a small molecule compound. As used herein, the term "small molecule compound" means a compound having a molecular weight of less than 1,500 daltons, preferably less than 1000 daltons. Preferably, the small molecule compound is effective to inhibit the function of a target selected from the group consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B  
25           protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, inosine monophosphate dehydrogenase ("IMPDH") and a nucleoside analog for the treatment of an HCV infection.

30           Certain illustrative HCV inhibitor compounds which can be administered with the compounds of the present invention include those disclosed in the following publications: WO 02/04425 A2 published January 17, 2002, WO 03/007945 A1 published January 30, 2003, WO 03/010141 A2 published February 6, 2003, WO 03/010142 A2 published February 6, 2003, WO 03/010143 A1 published February 6,

2003, WO 03/000254 A1 published January 3, 2003, WO 01/32153 A2 published  
 May 10, 2001, WO 00/06529 published February 10, 2000, WO 00/18231 published  
 April 6, 2000, WO 00/10573 published March 2, 2000, WO 00/13708 published  
 March 16, 2000, WO 01/85172 A1 published November 15, 2001, WO 03/037893  
 5 A1 published May 8, 2003, WO 03/037894 A1 published May 8, 2003, WO  
 03/037895 A1 published May 8, 2003, WO 02/100851 A2 published December 19,  
 2002, WO 02/100846 A1 published December 19, 2002, EP 1256628 A2 published  
 November 13, 2002, WO 99/01582 published January 14, 1999, WO 00/09543  
 published February 24, 2000.

10

Table 1 below lists some illustrative examples of compounds that can be  
 administered with the compounds of this invention. The compounds of the invention  
 can be administered with other anti-HCV activity compounds in combination  
 therapy, either jointly or separately, or by combining the compounds into a  
 15 composition.

**TABLE 1**

<b>Brand Name</b>	<b>Type of Inhibitor or Target</b>	<b>Source Company</b>
Omega IFN	IFN- $\omega$	BioMedicines Inc., Emeryville, CA
BILN-2061	serine protease inhibitor	Boehringer Ingelheim Pharma KG, Ingelheim, Germany
Summetrel	antiviral	Endo Pharmaceuticals Holdings Inc., Chadds Ford, PA
Roferon A	IFN- $\alpha$ 2a	F. Hoffmann-La Roche LTD, Basel, Switzerland
Pegasys	PEGylated IFN- $\alpha$ 2a	F. Hoffmann-La Roche LTD, Basel, Switzerland

<b>Brand Name</b>	<b>Type of Inhibitor or Target</b>	<b>Source Company</b>
Pegasys and Ribavirin	PEGylated IFN- $\alpha$ 2a/ribavirin	F. Hoffmann-La Roche LTD, Basel, Switzerland
CellCept	HCV IgG immunosuppressant	F. Hoffmann-La Roche LTD, Basel, Switzerland
Wellferon	lymphoblastoid IFN- $\alpha$ n1	GlaxoSmithKline plc, Uxbridge, UK
Albuferon - $\alpha$	albumin IFN- $\alpha$ 2b	Human Genome Sciences Inc., Rockville, MD
Levovirin	ribavirin	ICN Pharmaceuticals, Costa Mesa, CA
IDN-6556	caspase inhibitor	Idun Pharmaceuticals Inc., San Diego, CA
IP-501	antifibrotic	Indevus Pharmaceuticals Inc., Lexington, MA
Actimmune	INF- $\gamma$	InterMune Inc., Brisbane, CA
Infergen A	IFN alfacon-1	InterMune Pharmaceuticals Inc., Brisbane, CA
ISIS 14803	antisense	ISIS Pharmaceuticals Inc, Carlsbad, CA/Elan Pharmaceuticals Inc., New York, NY
JTK-003	RdRp inhibitor	Japan Tobacco Inc., Tokyo, Japan
Pegasys and Ceplene	PEGylated IFN- $\alpha$ 2a/immune modulator	Maxim Pharmaceuticals Inc., San Diego, CA
Ceplene	immune modulator	Maxim Pharmaceuticals Inc., San Diego, CA

<b>Brand Name</b>	<b>Type of Inhibitor or Target</b>	<b>Source Company</b>
Civacir	HCV IgG immunosuppressant	Nabi Biopharmaceuticals Inc., Boca Raton, FL
Intron A and Zadaxin	IFN- $\alpha$ 2b/ $\alpha$ 1-thymosin	RegeneRx Biopharmaceuticals Inc., Bethesda, MD/ SciClone Pharmaceuticals Inc, San Mateo, CA
Levovirin	IMPDH inhibitor	Ribapharm Inc., Costa Mesa, CA
Viramidine	IMPDH inhibitor	Ribapharm Inc., Costa Mesa, CA
Heptazyme	ribozyme	Ribozyme Pharmaceuticals Inc., Boulder, CO
Intron A	IFN- $\alpha$ 2b	Schering-Plough Corporation, Kenilworth, NJ
PEG-Intron	PEGylated IFN- $\alpha$ 2b	Schering-Plough Corporation, Kenilworth, NJ
Rebetron	IFN- $\alpha$ 2b/ribavirin	Schering-Plough Corporation, Kenilworth, NJ
Ribavirin	ribavirin	Schering-Plough Corporation, Kenilworth, NJ
PEG-Intron / Ribavirin	PEGylated IFN- $\alpha$ 2b/ribavirin	Schering-Plough Corporation,

<b>Brand Name</b>	<b>Type of Inhibitor or Target</b>	<b>Source Company</b>
		Kenilworth, NJ
Zadazim	immune modulator	SciClone Pharmaceuticals Inc., San Mateo, CA
Rebif	IFN- $\beta$ 1a	Serono, Geneva, Switzerland
IFN- $\beta$ and EMZ701	IFN- $\beta$ and EMZ701	Transition Therapeutics Inc., Ontario, Canada
T67	$\beta$ -tubulin inhibitor	Tularik Inc., South San Francisco, CA
VX-497	IMPDH inhibitor	Vertex Pharmaceuticals Inc., Cambridge, MA
VX-950/LY-570310	serine protease inhibitor	Vertex Pharmaceuticals Inc., Cambridge, MA/ Eli Lilly and Co. Inc., Indianapolis, IN
Omniferon	natural IFN- $\alpha$	Viragen Inc., Plantation, FL
XTL-002	monoclonal antibody	XTL Biopharmaceuticals Ltd., Rehovot, Isreal

The pharmaceutical compositions of this invention may be administered orally, parenterally or via an implanted reservoir. Oral administration or

5 administration by injection are preferred. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intra-

articular, intrasynovial, intrasternal, intrathecal, and intralesional injection or infusion techniques.

When orally administered, the pharmaceutical compositions of this invention  
5 may be administered in any orally acceptable dosage form including, but not limited  
to, capsules, tablets, and aqueous suspensions and solutions. In the case of tablets for  
oral use, carriers which are commonly used include lactose and corn starch.  
Lubricating agents, such as magnesium stearate, are also typically added. For oral  
administration in a capsule form, useful diluents include lactose and dried corn  
10 starch. When aqueous suspensions are administered orally, the active ingredient is  
combined with emulsifying and suspending agents. If desired, certain sweetening  
and/or flavoring and/or coloring agents may be added. Other suitable carriers for the  
above noted compositions can be found in standard pharmaceutical texts, e.g. in  
"Remington's Pharmaceutical Sciences", 19th ed., Mack Publishing Company,  
15 Easton, Penn., 1995.

The pharmaceutical compositions can be prepared by known procedures using  
well-known and readily available ingredients. The compositions of this invention  
may be formulated so as to provide quick, sustained or delayed release of the active  
20 ingredient after administration to the patient by employing procedures well known in  
the art. In making the compositions of the present invention, the active ingredient  
will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a  
carrier which may be in the form of a capsule, sachet, paper or other container.  
When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material  
25 which acts as a vehicle, excipient or medium for the active ingredient. Thus, the  
compositions can be in the form of tablets, pills, powders, beadlets, lozenges, sachets,  
elixirs, suspensions, emulsions, solutions, syrups, aerosols, (as a solid or in a liquid  
medium), soft and hard gelatin capsules, suppositories, sterile injectable solutions,  
sterile packaged powders and the like. Further details concerning the design and  
30 preparation of suitable delivery forms of the pharmaceutical compositions of the  
invention are known to those skilled in the art.

Dosage levels of between about 0.01 and about 1000 milligram per kilogram ("mg/kg") body weight per day, preferably between about 0.5 and about 250 mg/kg body weight per day of the compounds of the invention are typical in a monotherapy for the prevention and treatment of HCV mediated disease. Typically, the  
5 pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

10

As the skilled artisan will appreciate, lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of  
15 administration, rate of excretion, drug combination, the severity and course of the infection, the patient's disposition to the infection and the judgment of the treating physician. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the peptide. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In general,  
20 the compound is most desirably administered at a concentration level that will generally afford antivirally effective results without causing any harmful or deleterious side effects.

When the compositions of this invention comprise a combination of a  
25 compound of the invention and one or more additional therapeutic or prophylactic agent, both the compound and the additional agent are usually present at dosage levels of between about 10 to 100%, and more preferably between about 10 and 80% of the dosage normally administered in a monotherapy regimen.

30

When these compounds or their pharmaceutically acceptable enantiomers, diastereomers, salts, solvates or prodrugs are formulated together with a pharmaceutically acceptable carrier, the resulting composition may be administered

in vivo to mammals, such as man, to inhibit HCV NS3 protease or to treat or prevent HCV virus infection.

Accordingly, another aspect of this invention provides methods of inhibiting HCV NS3 protease activity in patients by administering a compound of the present invention or a pharmaceutically acceptable enantiomer, diastereomer, salt or solvate thereof.

In one aspect of the invention, there is provided a method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of the compound of the invention, or a pharmaceutically acceptable enantiomer, diastereomer, solvate, prodrug or salt thereof.

Preferably, the method of administering the compound is effective to inhibit the function of the HCV NS3 protease protein. In a preferred aspect, the method further comprises administering another compound having anti-HCV activity (as described above) prior to, after or concurrently with a compound of the invention.

The compounds of the invention may also be used as laboratory reagents. Compounds may be instrumental in providing research tools for designing of viral replication assays, validation of animal assay systems and structural biology studies to further enhance knowledge of the HCV disease mechanisms. Further, the compounds of the present invention are useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition.

The compounds of this invention may also be used to treat or prevent viral contamination of materials and therefore reduce the risk of viral infection of laboratory or medical personnel or patients who come in contact with such materials, e.g., blood, tissue, surgical instruments and garments, laboratory instruments and garments, and blood collection or transfusion apparatuses and materials.

Further, the compounds and compositions of the invention can be used for the manufacture of a medicament for treating HCV infection in a patient.

### EXAMPLES

5 The specific examples that follow illustrate the syntheses of the compounds of the instant invention, and are not to be construed as limiting the invention in sphere or scope. The methods may be adapted to variations in order to produce compounds embraced by this invention but not specifically disclosed. Further, variations of the methods to produce the same compounds in somewhat different manner will also be evident to one skilled in the art.

10

Solution percentages express a weight to volume relationship, and solution ratios express a volume to volume relationship, unless stated otherwise. Nuclear magnetic resonance (NMR) spectra were recorded either on a Bruker 300, 400 or 500 MHz spectrometer; the chemical shifts ( $\delta$ ) are reported in parts per million. Flash chromatography was carried out on silica gel (SiO<sub>2</sub>) according to Still's flash chromatography technique (W.C. Still et al., J. Org. Chem., (1978), 43, 2923).

15

All Liquid Chromatography (LC) data were recorded on a Shimadzu LC-10AS liquid chromatograph using a SPD-10AV UV-Vis detector and Mass Spectrometry (MS) data were determined with a Micromass Platform for LC in electrospray mode (ES+).

20

Unless otherwise noted, in the following examples each compound was analyzed by LC/MS, using one of seven methodologies, having the following conditions.

25

Columns: (Method A) - YMC ODS S7 C18 3.0x50 mm  
(Method B) - YMC ODS-A S7 C18 3.0x50 mm  
(Method C) - YMC S7 C18 3.0x50 mm  
(Method D) - YMC Xterra ODS S7 3.0x50 mm  
(Method E) - YMC Xterra ODS S7 3.0x50 mm  
(Method F) - YMC ODS-A S7 C18 3.0x50 mm  
(Method G) - YMC C18 S5 4.6x50 mm]

30

Gradient: 100% Solvent A/0% Solvent B to

0% Solvent A/100% Solvent B

Gradient time: 2 min. (A, B, D, F, G); 8 min. (C, E)

Hold time: 1 min. (A, B, D, F, G); 2 min. (C, E)

Flow rate: 5 mL/min

5 Detector Wavelength: 220 nm

Solvent A: 10% MeOH / 90% H<sub>2</sub>O / 0.1% TFA

Solvent B: 10% H<sub>2</sub>O / 90% MeOH / 0.1% TFA.

The abbreviations used in the present application, including particularly in the  
10 illustrative examples which follow, are well-known to those skilled in the art. Some  
of the abbreviations used are as follows:

	rt	room temperature
	Boc	tert-butyloxycarbonyl
15	DMSO	dimethylsulfoxide
	EtOAc	ethyl acetate
	t-BuOK	potassium t-butoxide
	Et <sub>2</sub> O	diethyl ether
	TBME	tert-butylmethyl ether
20	THF	tetrahydrofuran
	CDI	carbonyldiimidazole
	DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
	TFA	trifluoroacetic acid
	NMM	N-methylmorpholine
25	HATU	O-7-azabenzotriazol-1-yl
	HBTU	O-{1H-benzotriazol-1-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate
	HOBT	N-hydroxybenzotriazole
	PyBrop	bromo-bis-pyrrolidine-phosphonium hexafluorophosphate
30	DMF	dimethylformamide
	MeOH	methanol
	EDTA	ethylenediaminetetraacetic acid

	HRMS	high resolution mass spectrometry
	DMAP	4-dimethylaminopyridine
	DIPEA	diisopropylethylamine
	DCM	dichloromethane
5	DCE	dichloroethane

The compounds and chemical intermediates of the present invention, described in the following examples, were prepared according to the following methods. It should be noted that the following exemplification section is presented in  
10 sections. Example numbers and compound numbers are not contiguous throughout the entire Examples portion of the application and hence, each section indicates a “break” in the numbering. The numbering within each section is generally contiguous.

15 **Section A:**

Preparation of Intermediates:


**Preparation of P1 Intermediates:**

The P1 intermediates described in this section can be used to prepare compounds of  
20 Formula I by the methods described herein.

**I P1 elements:**


**1. Preparation of racemic (1*R*,2*S*)/(1*S*,2*R*)-1-amino-2-vinylcyclopropane  
carboxylic acid ethyl ester**

25




**Method A**

**Step 1**



Glycine ethyl ester hydrochloride (303.8 g, 2.16 mole) was suspended in *tert*-butylmethyl ether (1.6 L). Benzaldehyde (231 g, 2.16 mole) and anhydrous sodium sulfate (154.6 g, 1.09 mole) were added and the mixture cooled to 0 °C using an ice-water bath. Triethylamine (455 mL, 3.26 mole) was added dropwise over 30 min and the mixture stirred for 48 h at rt. The reaction was then quenched by addition of ice-cold water (1 L) and the organic layer was separated. The aqueous phase was extracted with *tert*-butylmethyl ether (0.5 L) and the combined organic phases washed with a mixture of saturated aqueous NaHCO<sub>3</sub> (1 L) and brine (1 L). The solution was dried over MgSO<sub>4</sub>, concentrated in vacuo to afford 392.4 g of the *N*-benzyl imine product as a thick yellow oil that was used directly in the next step. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.32 (t, *J*=7.1 Hz, 3H), 4.24 (q, *J*=7.1 Hz, 2H), 4.41 (d, *J*=1.1 Hz, 2H), 7.39-7.47 (m, 3H), 7.78-7.81 (m, 2H), 8.31 (s, 1H).

15



To a suspension of lithium *tert*-butoxide (84.06 g, 1.05 mol) in dry toluene (1.2 L), was added dropwise a mixture of the *N*-benzyl imine of glycine ethyl ester (100.4 g, 0.526 mol) and *trans*-1,4-dibromo-2-butene (107.0 g, 0.500 mol) in dry toluene (0.6 L) over 60 min. After completion of the addition, the deep red mixture was quenched by addition of water (1 L) and *tert*-butylmethyl ether (TBME, 1 L). The aqueous phase was separated and extracted a second time with TBME (1 L). The organic phases were combined, 1 N HCl (1 L) was added and the mixture stirred

25


at room temperature for 2 h. The organic phase was separated and extracted with water (0.8 L). The aqueous phases were then combined, saturated with salt (700 g), TBME (1 L) was added and the mixture cooled to 0 °C. The stirred mixture was then basified to pH 14 by the dropwise addition of 10 N NaOH, the organic layer

5 separated, and the aqueous phase extracted with TBME (2 x 500 mL). The combined organic extracts were dried (MgSO<sub>4</sub>) and concentrated to a volume of 1L. To this solution of free amine, was added BOC<sub>2</sub>O or di-*tert*-butyldicarbonate (131.0 g, 0.6 mol) and the mixture stirred 4 days at rt. Additional di-*tert*-butyldicarbonate (50 g, 0.23 mol) was added to the reaction, the mixture refluxed for 3 h, and was then

10 allowed cool to room temperature overnight. The reaction mixture was dried over MgSO<sub>4</sub> and concentrated in vacuo to afford 80 g of crude material. This residue was purified by flash chromatography (2.5 Kg of SiO<sub>2</sub>, eluted with 1% to 2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to afford 57 g (53%) of racemic *N*-Boc-(1*R*,2*S*)/(1*S*,2*R*)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester as a yellow oil which solidified while

15 sitting in the refrigerator: <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 1.26 (t, *J*=7.1 Hz, 3H), 1.46 (s, 9H), 1.43-1.49 (m, 1H), 1.76-1.82 (br m, 1H), 2.14 (q, *J*=8.6 Hz, 1H), 4.18 (q, *J*=7.2 Hz, 2H), 5.12 (dd *J*=10.3, 1.7 Hz, 1H), 5.25 (br s, 1H), 5.29 (dd, *J*=17.6, 1.7 Hz, 1H), 5.77 (ddd, *J*=17.6, 10.3, 8.9 Hz, 1H); MS *m/z* 254.16 (M-1)

20 Step 3 Preparation of Racemic (1*R*,2*S*)/(1*S*,2*R*) 1-amino-2-vinylcyclopropane carboxylic acid ethyl ester hydrochloride




25 *N*-Boc-(1*R*,2*S*)/(1*S*,2*R*)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester (9.39 g, 36.8 mmol) was dissolved in 4 N HCl/dioxane (90 ml, 360 mmol) and was stirred for 2 h at rt. The reaction mixture was concentrated to supply (1*R*,2*S*)/(1*S*,2*R*)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester hydrochloride in quantitative yield (7 g, 100%). <sup>1</sup>H NMR (methanol-*d*<sub>4</sub>) δ 1.32 (t, *J*=7.1, 3H), 1.72 (dd, *J*=10.2, 6.6 Hz, 1H), 1.81 (dd, *J*=8.3, 6.6 Hz, 1H), 2.38 (q,

30

$J=8.3$  Hz, 1H), 4.26-4.34 (m, 2H), 5.24 (dd, 10.3, 1.3 Hz, 1H) 5.40 (d,  $J=17.2$ , 1H), 5.69-5.81 (m, 1H).

5 **Alternate route for the preparation of Racemic N-Boc-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester hydrochloride**




10 To a solution of potassium *tert*-butoxide (11.55 g, 102.9 mmol) in THF (450 mL) at  $-78$  °C was added the commercially available *N,N*-dibenzyl imine of glycine ethyl ester (25.0 g, 93.53 mmol) in THF (112 mL). The reaction mixture was warmed to  $0$  °C, stirred for 40 min, and was then cooled back to  $-78$  °C. To this solution was added *trans*-1,4-dibromo-2-butene (20.0 g, 93.50 mmol), the mixture

15 stirred for 1 h at  $0$  °C and was cooled back to  $-78$  °C. Potassium *tert*-butoxide (11.55 g, 102.9 mmol) was added, the mixture immediately warmed to  $0$  °C, and was stirred one more hour before concentrating in vacuo. The crude product was taken up in Et<sub>2</sub>O (530 mL), 1N aq. HCl solution (106 mL, 106 mmol) added and the resulting biphasic mixture stirred for 3.5 h at rt. The layers were separated and the aqueous

20 layer was washed with Et<sub>2</sub>O (2x) and basified with a saturated aq. NaHCO<sub>3</sub> solution. The desired amine was extracted with Et<sub>2</sub>O (3x) and the combined organic extract was washed with brine, dried (MgSO<sub>4</sub>), and concentrated in vacuo to obtain the free amine. This material was treated with a 4N HCl solution in dioxane (100 mL, 400 mmol) and concentrated to afford (1*R*,2*S*)/(1*S*,2*R*)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester hydrochloride as a brown semisolid (5.3 g, 34% yield)

25 identical to the material obtained from procedure A, except for the presence of a small unidentified aromatic impurity (8%).

### Resolution of *N*-Boc-(1*R*,2*S*)/(1*S*,2*R*)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester




5


#### Resolution A

To an aqueous solution of sodium phosphate buffer (0.1 M, 4.25 liter ("L"), pH 8) housed in a 12 Liter jacketed reactor, maintained at 39°C, and stirred at 300 rpm was added 511 grams of Alcalase 2.4L (about 425 mL) (Novozymes North America Inc.). When the temperature of the mixture reached 39°C, the pH was adjusted to 8.0 by the addition of a 50% NaOH in water. A solution of the racemic *N*-Boc-(1*R*,2*S*)/(1*S*,2*R*)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester (85g) in 850 mL of DMSO was then added over a period of 40 min. The reaction temperature was then maintained at 40°C for 24.5h during which time the pH of the mixture was adjusted to 8.0 at the 1.5h and 19.5h time points using 50% NaOH in water. After 24.5h, the enantio-excess of the ester was determined to be 97.2%, and the reaction was cooled to room temperature (26°C) and stirred overnight (16h) after which the enantio-excess of the ester was determined to be 100%. The pH of the reaction mixture was then adjusted to 8.5 with 50% NaOH and the resulting mixture was extracted with MTBE (2 x 2 L). The combined MTBE extract was then washed with 5% NaHCO<sub>3</sub> (3 x 100 mL), water (3 x 100 mL), and evaporated *in vacuo* to give the enantiomerically pure *N*-Boc-(1*R*,2*S*)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester as light yellow solid (42.55 g; purity: 97% @ 210 nm, containing no acid; 100% enantiomeric excess ("ee").

The aqueous layer from the extraction process was then acidified to pH 2 with 50% H<sub>2</sub>SO<sub>4</sub> and extracted with MTBE (2 x 2 L). The MTBE extract was washed with water (3 x 100 mL) and evaporated to give the acid as light yellow solid (42.74 g; purity: 99% @ 210 nm, containing no ester).



1R, 2S-ester



1S,2R-acid

5

	ester		acid	
High Resolution Mass Spec	(+ ESI, C <sub>13</sub> H <sub>22</sub> NO <sub>4</sub> , [M+H] <sup>+</sup> , cal. 256.1549, found 256.1542		(- ESI, C <sub>11</sub> H <sub>16</sub> NO <sub>4</sub> , [M-H] <sup>-</sup> , cal. 226.1079, found 226.1089	
NMR observed chemical shift				
Solvent: CDCl <sub>3</sub> (proton δ 7.24 ppm, C-13 δ 77.0 ppm)				
Bruker DRX-500C: proton 500.032 MHz, carbon 125.746 MHz				
Position	Proton (pattern) ppm	C-13 ppm	Proton (pattern) ppm	C-13 ppm
1	----	40.9	----	40.7
2	2.10 (q, J = 9.0 Hz)	34.1	2.17 (q, J = 9.0 Hz)	35.0
3a	1.76 (br)	23.2	1.79 (br)	23.4
3b	1.46 (br)		1.51, (br)	
4	----	170.8	----	175.8
5	5.74 (ddd, J = 9.0, 10.0, 17.0 Hz)	133.7	5.75 (m)	133.4
6a	5.25 (d, J = 17.0 Hz)	117.6	5.28 (d, J = 17.0 Hz)	118.1

6b	5.08 (dd, J = 10.0, 1.5 Hz)		5.12 (d, J = 10.5 Hz)	
7	----	155.8	----	156.2
8	----	80.0	----	80.6
9	1.43 (s)	28.3	1.43 (s)	28.3
10	4.16 (m)	61.3	----	----
11	1.23 (t, J = 7.5 Hz)	14.2	----	----

### Resolution B

To 0.5 mL 100 mM Heps•Na buffer (pH 8.5) in a well of a 24 well plate  
 5 (capacity: 10 ml/well), 0.1 mL of Savinase 16.0L (protease from *Bacillus clausii*)  
 (Novozymes North America Inc.) and a solution of the racemic *N*-Boc-  
 (1*R*,2*S*)/(1*S*,2*R*)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester (10 mg) in  
 0.1 mL of DMSO were added. The plate was sealed and incubated at 250 rpm at  
 40°C. After 18h, enantio-excess of the ester was determined to be 44.3% as  
 10 following: 0.1 mL of the reaction mixture was removed and mixed well with 1 mL  
 ethanol; after centrifugation, 10 microliter (“μl”) of the supernatant was analyzed  
 with the chiral HPLC. To the remaining reaction mixture, 0.1 mL of DMSO was  
 added, and the plate was incubated for additional 3 days at 250 rpm at 40°C, after  
 15 which four mL of ethanol was added to the well. After centrifugation, 10 μl of the  
 supernatant was analyzed with the chiral HPLC and enantio-excess of the ester was  
 determined to be 100%.

### Resolution C

20 To 0.5 ml 100 mM Heps•Na buffer (pH 8.5) in a well of a 24 well plate  
 (capacity: 10 mL/well), 0.1 ml of Esperase 8.0L, (protease from *Bacillus*  
*halodurans*) (Novozymes North America Inc.) and a solution of the racemic *N*-Boc-  
 (1*R*,2*S*)/(1*S*,2*R*)-1-amino-2-vinylcyclopropane carboxylic acid ethyl ester (10 mg) in  
 0.1 mL of DMSO were added. The plate was sealed and incubated at 250 rpm at  
 25 40°C. After 18 hour, enantio-excess of the ester was determined to be 39.6% as

following: 0.1 mL of the reaction mixture was removed and mixed well with 1 mL ethanol; after centrifugation, 10  $\mu$ l of the supernatant was analyzed with the chiral HPLC. To the remaining reaction mixture, 0.1 mL of DMSO was added, and the plate was incubated for additional 3 days at 250 rpm at 40°C, after which four mL of ethanol was added to the well. After centrifugation, 10  $\mu$ l of the supernatant was analyzed with the chiral HPLC and enantio-excess of the ester was determined to be 100%.

Samples analysis was carried out in the following manner:

10

1) Sample preparation: About 0.5 ml of the reaction mixture was mixed well with 10 volume of EtOH. After centrifugation, 10  $\mu$ l of the supernatant was injected onto HPLC column.

15 2) Conversion determination:

Column: YMC ODS A, 4.6 x 50 mm, S-5  $\mu$ m

Solvent: A, 1 mM HCl in water; B, MeCN

Gradient: 30% B for 1 min; 30% to 45% B over 0.5 min; 45% B for 1.5 min; 45% to 30% B over 0.5 min.

20 Flow rate: 2 ml/min

UV Detection: 210 nm

Retention time: acid, 1.2 min; ester, 2.8 min.

3) Enantio-excess determination for the ester:

25 Column: CHIRACEL OD-RH, 4.6 x 150 mm, S-5  $\mu$ m

Mobile phase: MeCN/50 mM HClO<sub>4</sub> in water (67/33)

Flow rate: 0.75 ml/min.

UV Detection: 210 nm.


Retention time:

30 (1S, 2R) isomer as acid: 5.2 min;

Racemate: 18.5 min and 20.0 min;

(1R, 2S) isomer as ester: 18.5 min.

## 2. Preparation of *N*-Boc-(1*R*,2*S*)-1-amino-2-cyclopropylcyclopropane carboxylic acid ethyl ester




5

A solution of *N*-Boc-(1*R*,2*S*)-1-amino-2-vinylcyclopropane carboxylic acid (255 mg, 1.0 mmol) in ether (10 mL) was treated with palladium acetate (5 mg, 0.022 mmol). The orange/red solution was placed under an atmosphere of N<sub>2</sub>. An excess of diazomethane in ether was added dropwise over the course of 1 h. The resulting solution was stirred at rt for 18 h. The excess diazomethane was removed using a stream of nitrogen. The resulting solution was concentrated by rotary evaporation to give the crude product. Flash chromatography (10% EtOAc/hexane) provided 210 mg (78%) of *N*-Boc-(1*R*,2*S*)-1-amino-2-cyclopropylcyclopropane carboxylic acid ethyl ester as a colorless oil. LC-MS (retention time: 2.13, similar to method A except: gradient time 3 min, Xterra MS C18 S7 3.0 x 50mm column), MS m/e 270 (M<sup>+</sup>+1).

10


15

## 3. 1-tert-butoxycarbonylamino-cyclopropane-carboxylic acid is commercially available



20

## 4. Preparation of 1-aminocyclobutanecarboxylic acid methyl ester·hydrochloride




1-aminocyclobutanecarboxylic acid (100 mg, 0.869 mmol)(Tocris) was dissolved in 10 mL of MeOH, HCl gas was bubbled in for 2h. The reaction mixture was stirred

25

for 18 h, and then concentrated in vacuo to give 144 mg of a yellow oil. Trituration with 10 mL of ether provided 100 mg of the titled product as a white solid.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  2.10-2.25 (m, 1H), 2.28-2.42 (m, 1H), 2.64-2.82 (m, 4H), 3.87 (s, 3H), 9.21 (br s, 3H).


5

**5. Preparation of racemic (1*R*,2*R*)/(1*S*,2*S*) 1-Amino-2-ethylcyclopropanecarboxylic acid *tert*-butyl ester, shown below.**




ethyl syn to carboxy

10 Step 1: Preparation of 2-Ethylcyclopropane-1,1-dicarboxylic acid di-*tert*-butyl ester, shown below.




To a suspension of benzyltriethylammonium chloride (21.0 g, 92.2 mmol) in a 50%  
15 aqueous NaOH solution (92.4 g in 185 mL  $\text{H}_2\text{O}$ ) was added 1,2-dibromobutane (30.0 g, 138.9 mmol) and di-*tert*-butylmalonate (20.0 g, 92.5 mmol). The reaction mixture was vigorously stirred 18 h at rt, a mixture of ice and water was then added. The crude product was extracted with  $\text{CH}_2\text{Cl}_2$  (3x) and sequentially washed with water (3x), brine and the organic extracts combined. The organic layer was dried ( $\text{MgSO}_4$ ),  
20 filtered and concentrated in vacuo. The resulting residue was flash chromatographed (100 g  $\text{SiO}_2$ , 3%  $\text{Et}_2\text{O}$  in hexane) to afford the titled product (18.3 g, 67.8 mmol, 73% yield) which was used directly in the next reaction.

Step 2: Preparation of racemic 2-Ethylcyclopropane-1,1-dicarboxylic acid *tert*-butyl ester, shown below.




The product of Step 1 (18.3 g, 67.8 mmol) was added to a suspension of potassium tert-butoxide (33.55 g, 299.0 mmol) in dry ether (500 mL) at 0 °C, followed by H<sub>2</sub>O (1.35 mL, 75.0 mmol) and was vigorously stirred overnight at rt. The reaction mixture was poured in a mixture of ice and water and washed with ether (3x). The aqueous layer was acidified with a 10% aq. citric acid solution at 0°C and extracted with EtOAc (3x). The combined organic layers were washed with water (2x), brine, dried (MgSO<sub>4</sub>) and concentrated in vacuo to afford the titled product as a pale yellow oil (10 g, 46.8 mmol, 69% yield).

Step 3: Preparation of (1*R*,2*R*)/(1*S*,2*S*) 2-Ethyl-1-(2-trimethylsilyl ethoxycarbonylamino)cyclopropane-carboxylic acid tert-butyl ester, shown below.



To a suspension, of the product of Step 2 (10 g, 46.8 mmol) and 3 g of freshly activated 4A molecular sieves in dry benzene (160 mL), was added Et<sub>3</sub>N (7.50 mL, 53.8 mmol) and DPPA (11 mL, 10.21 mmol). The reaction mixture was refluxed for 3.5 h, 2-trimethylsilyl-ethanol (13.5 mL, 94.2 mmol) was then added, and the reaction mixture was refluxed overnight. The reaction mixture was filtered, diluted with Et<sub>2</sub>O, washed with a 10% aqueous citric acid solution, water, saturated aqueous NaHCO<sub>3</sub>, water (2x), brine (2X), dried (MgSO<sub>4</sub>) and concentrated in vacuo. The residue was suspended with 10g of Aldrich polyisocyanate scavenger resin in 120 mL of CH<sub>2</sub>Cl<sub>2</sub>, stirred at rt overnight and filtered to afford the titled product (8 g, 24.3 mmol; 52%) as a pale yellow oil: <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 0.03 (s, 9H), 0.97 (m, 5H), 1.20 (bm, 1H), 1.45 (s, 9H), 1.40-1.70 (m, 4H), 4.16 (m, 2H), 5.30 (bs, 1H).


Step 4: Preparation of racemic (1*R*,2*R*)/(1*S*,2*S*) 1-Amino-2-ethylcyclopropanecarboxylic acid *tert*-butyl ester, shown below.



ethyl syn to carboxy


To the product of Step 3 (3 g, 9 mmol) was added a 1.0 M TBAF solution in THF (9.3 mL, 9.3 mmol) and the mixture heated to reflux for 1.5 h, cooled to rt and then diluted with 500 ml of EtOAc. The solution was successively washed with water  
 5 (2x100 mL), brine (2x100 mL), dried (MgSO<sub>4</sub>), concentrated in vacuo to provide the title intermediate

### 6.Preparation of 1-Amino-spiro[2.3]hexane-1-carboxylic acid methyl ester hydrochloride salt




10

Step 1 Preparation of [2,3]hexane-1,1-dicarboxylic acid dimethyl ester, shown below.



To a mixture of methylene-cyclobutane (1.5 g, 22 mmol) and Rh<sub>2</sub>(OAc)<sub>4</sub> (125 mg, 0.27 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (15 mL) was added 3.2 g (20 mmol) of dimethyl  
 15 diazomalonate (prepared according to J. Lee et al. *Synth. Comm.*, 1995, 25, 1511-1515) at 0°C over a period of 6 h. The reaction mixture was then warmed to rt and stirred for another 2 h. The mixture was concentrated and purified by flash chromatography (eluting with 10:1 hexane/Et<sub>2</sub>O to 5:1 hexane/Et<sub>2</sub>O) to give 3.2 g (72%) of [2,3]hexane-1,1-dicarboxylic acid dimethyl ester as a yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.78 (s, 6 H), 2.36 (m, 2 H), 2.09 (m, 3 H), 1.90 (m, 1 H), 1.67  
 20 (s, 2 H). LC-MS: MS m/z 199 (M<sup>+</sup>+1).

Step 2: Preparation of spiro[2,3]hexane-1,1-dicarboxylic acid methyl ester, shown below.




To the mixture of spiro [2,3]hexane-1,1-dicarboxylic acid dimethyl ester (200 mg, 1.0 mmol) in 2 mL of MeOH and 0.5 mL of water was added KOH (78 mg, 1.4 mmol). This solution was stirred at rt for 2 days. It was then acidified with dilute HCl  
 5 and extracted two times with ether. The combined organic phases were dried (MgSO<sub>4</sub>) and concentrated to yield 135 mg (73%) of 2 as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.78 (s, 3 H), 2.36-1.90 (m, 8 H). LC-MS: MS m/z 185 (M<sup>+</sup>+1)


Step 3: Preparation of the titled product, 1-amino-spiro[2.3]hexane-1-carboxylic acid  
 10 methyl ester hydrochloride salt.

To a mixture of spiro[2,3]hexane-1,1-dicarboxylic acid methyl ester (660 mg, 3.58 mmol) in 3 mL of anhydrous t-BuOH was added 1.08 g (3.92 mmol) of DPPA and 440 mg (4.35 mmol) of Et<sub>3</sub>N. The mixture was heated at reflux for 21 h and then  
 15 partitioned between H<sub>2</sub>O and ether. The ether phase was dried over magnesium sulfate, filtered and concentrated in vacuo to yield an oil. To this oil was added 3 mL of a 4 M HCl/dioxane solution. This acidic solution was stirred at rt for 2 h and then concentrated in vacuo. The residue was triturated with ether to give 400 mg (58 %) of  
 20 desired product as a white solid. <sup>1</sup>H NMR (300 MHz, d<sub>6</sub>-DMSO) δ 8.96 (br s, 3 H), 3.71 (s, 3 H), 2.41 (m, 1 H), 2.12 (m, 4 H), 1.93 (m, 1 H), 1.56 (q, 2 H, J=8 Hz). LC-MS of free amine: MS m/z 156 (M<sup>+</sup>+1).

**7. Preparation of 1-Amino-spiro[2.4]heptane-1-carboxylic acid methyl ester  
 25 hydrochloride salt, shown below, was prepared as follows.**




Step 1: Spiro[2.4]heptane-1,1-dicarboxylic acid dimethyl ester, shown below, was prepared as follows.



Using the same procedure described in the preparation of 1-Amino-spiro[2.3]hexane-1-carboxylic acid methyl ester hydrochloride salt

1.14g (13.9 mmol) of methylenecyclopentane and 2.0 g (12.6 mmol) of dimethyl  
 5 diazomalonate were reacted to yield 1.8 g (67%) of the dimethyl ester.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  3.73 (s, 6 H), 1.80 (m, 2 H), 1.70 (m, 4 H), 1.60 (m, 4 H). LC-MS: MS m/z 213 ( $\text{M}^+ + 1$ ).


Step 2: Preparation of Spiro[2.4]heptane-1,1-dicarboxylic acid methyl ester, shown  
 10 below, was prepared as follows.



Using the same procedure described in the preparation of 1-Amino-spiro[2.3]hexane-1-carboxylic acid methyl ester hydrochloride salt

1.7 g (8.0 mmol) of the product of Step 1 and 493 mg (8.8 mmol) of KOH gave 1.5 g  
 15 (94%) of spiro[2.4]heptane-1,1-dicarboxylic acid methyl ester.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  3.80 (s, 3 H), 2.06 (d, 1 H,  $J=5$  Hz), 1.99 (d, 1 H,  $J=5$  Hz), 1.80–1.66 (m, 8 H). LC-MS: MS m/z 199 ( $\text{M}^+ + 1$ ).

Step 3: Preparation of 1-Amino-spiro[2.4]heptane-1-carboxylic acid methyl ester  
 20 hydrochloride salt, shown below, was prepared as follows.




Using the same procedure described above in preparation of 1-Amino-spiro[2.3]hexane-1-carboxylic acid methyl ester hydrochloride salt, 500 mg (2.5  
 25 mmol) of the product of Step 2, 705 mg (2.5 mmol) of DPPA and 255 mg (2.5 mmol)


of Et<sub>3</sub>N gave 180 mg (35%) of this hydrochloride salt. <sup>1</sup>H NMR (300 MHz, d<sub>6</sub>-DMSO) δ 8.90 (br s, 3 H), 3.74 (s, 3 H), 1.84 (m, 1 H), 1.69 (m, 4 H), 1.58 (m, 4 H), 1.46 (d, 1 H, *J*=6 Hz). LC-MS of free amine: MS *m/z* 170 (*M*<sup>+</sup>+1).

5

**8. Preparation of 1-Amino-spiro[2.2]pentane-1-carboxylic acid methyl ester hydrochloride salt, shown below, was prepared as follows.**




Step 1: Spiro[2.2]pentane-1,1-dicarboxylic acid dimethyl ester, shown below, was prepared as follows.



To a mixture of methylenecyclopropane (1.0 g, 18.5 mmol)(prepared according to P. Binger US Patent Serial No. 5,723,714) and Rh<sub>2</sub>(OAc)<sub>4</sub> (82mg, 0.185 mmol) in anhydrous CH<sub>2</sub>Cl<sub>2</sub> (10 mL), was added dimethyl diazomalonate (2.9 g, 18.3 mmol) at 0°C. At the top of the flask was installed a cold finger, the temperature of which was kept at -10°C. The reaction mixture was warmed to rt and stirred for another 2 h. The mixture was concentrated in vacuo and purified by flash chromatography (eluting with 10:1 hexane/Et<sub>2</sub>O to 5:1 hexane/Et<sub>2</sub>O) to give 0.85 g (25%) of the dimethyl ester as a yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 3.73 (s, 6 H), 1.92 (s, 2 H), 1.04 (d, 4 H, *J*=3 Hz).

20

Step 2: Spiro[2.2]pentane-1,1-dicarboxylic acid methyl ester, shown below, was prepared as follows.




Using the same procedure described above in preparation of 1-Amino-spiro[2.3]hexane-1-carboxylic acid methyl ester hydrochloride salt, 800 mg (4.3 mmol) of the product of step 1 and 240 mg (4.3 mmol) of KOH gave 600 mg (82%)

25

of Spiro[2.2]pentane-1,1-dicarboxylic acid methyl ester.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  3.82 (s, 6 H), 2.35 (d, 1 H,  $J=3$  Hz), 2.26 (d, 1 H,  $J=3$  Hz), 1.20 (m, 1 H), 1.15 (m, 1 H), 1.11 (m, 1 H), 1.05 (m, 1 H). LRMS: MS  $m/z$  169 ( $\text{M}^+-1$ ) (Method D).

5


Step 3: 1-Amino-spiro[2.2]pentane-1-carboxylic acid methyl ester hydrochloride salt, shown below, was prepared as follows.



Using the same procedure described above for the preparation of 1-Amino-spiro[2.3]hexane-1-carboxylic acid methyl ester hydrochloride salt, 400 mg (2.3 mmol) of the product of step 2, 700 mg (2.5 mmol) of DPPA and 278 mg (2.7 mmol) of  $\text{Et}_3\text{N}$  gave 82 mg (20%) of the hydrochloride salt.  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ )  $\delta$  9.19 (br s, 3 H), 3.81 (s, 3 H), 2.16, (d,  $J=5.5$  Hz, 1 H), 2.01 (d,  $J=5.5$  Hz, 1 H), 1.49 (m, 1 H), 1.24, (m, 1 H), 1.12 (m, 2 H). LRMS of free amine: MS  $m/z$  142 ( $\text{M}^++1$ ).

15

**9. Preparation of 5-Amino-spiro[2.3]hexane-5-carboxylic acid ethyl ester, shown below, was prepared as follows.**




20 Spiro[2.3]hexan-4-one (500 mg, 5 mmol), which was prepared from bicyclopropylidene (A. Meijere et al. *Org. Syn.* 2000, 78, 142-151) according to A. Meijere et al. *J. Org. Chem.* 1988, 53, 152-161, was combined with ammonium carbamate (1.17 g, 15 mmol) and potassium cyanide (812 mg, 12.5 mmol) in 50 mL of EtOH and 50 mL of water. The mixture was heated at 55 °C for 2 days. Then  
25 NaOH (7 g, 175 mmol) was added and the solution was heated under reflux overnight. The mixture was then chilled to 0 °C, acidified to pH 1 with concentrated HCl, and concentrated in vacuo. EtOH was added to the crude amino acid mixture and then concentrated to dryness (5x) so as to remove residual water. The residue dissolved in 100 mL of EtOH was cooled to 0 °C. It was then treated with 1 mL of

SOCl<sub>2</sub> and refluxed for 3 days. The solids were removed by filtration, and the filtrate was concentrated in vacuo to give the crude product. The crude product was partitioned between 3 N NaOH, NaCl and EtOAc. The organic phase was dried over potassium carbonate and concentrated. The residue was purified using column chromatography on C18 silica gel (eluting with MeOH/H<sub>2</sub>O) to yield 180 mg (21%) of 15 as an oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.20 (br s, 2 H), 4.27 (s, 2 H), 2.80 (s, 1 H), 2.54 (s, 1 H), 2.34 (m, 2 H), 1.31 (s, 3 H), 1.02 (s, 1 H), 0.66 (m, 3 H). <sup>13</sup>C NMR (300 MHz, CDCl<sub>3</sub>) δ 170.2(s), 63.0(s), 62.8 (s), 26.1 (s), 26.0 (s), 24.9 (s), 13.9 (s), 11.4 (s), 10.9 (s). LC-MS: MS m/z 170 (M<sup>+</sup>+1).

10

## II Heterocycles to be used as starting material in the construction of P2 elements for subsequent incorporation into compounds of Formula I.

### 1. Isoquinolines





15

Isoquinoline (1) and substituted analogues thereof, can be incorporated into P2 elements using the two methods outline above and described in detail herein. Said P2 elements (3) can then be converted into compounds of Formula I using procedures analogous to those described herein for similar isoquinoline analogues.

20

## 2. Isoxazolepyridine and Oxazolepyridine(1)



Isoxazole and oxazole heterocycle (1) and analogues thereof can be prepared using know chemistry and incorporated into compounds of Formula I using the chemistry described herein for similar isoxazolepyridine intermediates as shown in section B.

**Section B**

## Preparation of Compounds


10 The following LC MS conditions were used in the synthesis of the compounds in section B

LC-MS condition:

Columns: (Method A) - Xterra S7 C18 3.0x50 mm


15

**Example 1000: Preparation of Intermediate 1.**



Intermediate 1

Scheme 1



## Step 1:

To a solution of 3-methoxy cinnamic acid (11.04 g, 62 mmol) and triethylamine (12.52 g, 124 mmol) in acetone (80 mL) was added ethyl chloroformate (approximately 1.5 equivalents) dropwise at 0°C. After stirring at this temperature for 1 h, aqueous NaN<sub>3</sub> (6.40 g, 100 mmol in 35 mL H<sub>2</sub>O) was added dropwise and the reaction mixture was stirred for 16 h at the ambient temperature. Water (100 mL) was added to the mixture and the volatile was removed in vacuo. The resulting slurry was extracted with toluene (3X50 mL) and the combined organic layers were dried over MgSO<sub>4</sub>. This dried solution was added dropwise to a heated solution of diphenylmethane (50 mL) and tributylamine (30 mL) at 190°C. The toluene was distilled off as added. After complete addition, the reaction temperature was raised to 210°C for 2 h. After cooling, the precipitated product was collected by filtration, washed with hexane (2X50 mL), and dried to yield the desired product as a white solid (5.53 g, 51%) (Nicolas Briet *et al*, Tetrahedron, 2002, 5761-5766).

LC-MS (retention time: 0.82 min, method B), MS *m/z* 176 (M<sup>+</sup>+H).


## Step 2:

6-Methoxy-2H-isoquinolin-1-one (5.0 g, 28.4 mmol) in POCl<sub>3</sub> (10 mL) was heated to gentle reflux for 3 h the evaporated *in vacuo* (Nicolas Briet *et al*, Tetrahedron, 2002, 5761-5766). The residue was poured into iced water (20 mL) and neutralized to pH 10 with 10 M NaOH. Extracted with CHCl<sub>3</sub>. The organic layer was washed with brine, dried

over MgSO<sub>4</sub>, filtered, evaporated. The residue was purified by flash chromatography (1:1 hexane-EtOAc) to afford 4.41 g (80%) of the desired product as a white solid.

<sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 3.98 (s, 3H), 7.34-7.38 (m, 2 H), 7.69 (d, *J*=5.5 Hz, 1H), 8.10 (d, *J*=6.0 Hz, 1H), 8.23 (d, *J*=9.5 Hz, 1H);

5 LC-MS (retention time: 1.42 min, method B), MS *m/z* 194 (M<sup>+</sup>+H).




Step 3:

To a solution of N-BOC-3-(*R*)-hydroxy-L-proline (892 mg, 3.89 mmol) in DMSO (40 mL) at the ambient temperature was added potassium tert-butoxide (1.34 g, 12.0 mmol) in one portion. The formed suspension was stirred at this temperature for 30 min before being cooled to 10<sup>0</sup>C. 1-chloro-6-methoxy-isoquinolin (785 mg, 4.05 mmol) was added as solid in one portion and the final mixture was stirred at the ambient temperature for 12 h. Quenched with iced 5% citric acid (aq), extracted with EtOAc (100 mL). The aqueous phase was extracted with EtOAc again. The combined organic layers were washed with 5% citric acid (aq) and brine respectively, dried over MgSO<sub>4</sub>, filtered. The filtrate was evaporated in vacuo to dryness to yield 1.49 g (99%) of the desired product as an off-white foam. This material was used in the next step reaction as crude without further purification.


<sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 1.42, 1.44 (rotamers, 9H), 2.38-2.43 (m, 1H), 2.66-2.72 (m, 1H), 3.80-3.87 (m, 2H), 3.92 (s, 3H), 4.44-4.52 (m, 1H), 5.73 (b, 1H), 7.16-7.18 (m, 2H), 7.24-7.25 (m, 1H), 7.87-7.88 (m, 1H), 8.07 (d, *J*=8.5 Hz, 1H);

LC-MS (retention time: 1.62 min, method B), MS *m/z* 389 (M<sup>+</sup>+H).

25 Example 1001 Preparation of Compound 1001



compound 1001



## 5 step 1:

A slurry of P2 Boc-(4R)-(6-methoxy-isoquinoline-1-oxo)-S-proline]-P1(1R,2S Vinyl  
 Acca)-COOEt (7.88 g, 14.99 mmol) in 4M HCl/dioxane (120 mL, 480 mmol) was  
 stirred for 2 h, removed the solvent in vacuo and azeotroped with dry dioxane. To the  
 10 residue was added DMF (75 mL), N-methylmorpholine (6.27 mL, 57.07 mmol), Boc-  
*L-tert-leucine* (5.20 g, 22.49 mmol), and HATU (8.53 g, 22.49 mmol). The reaction  
 mixture was stirred at rt overnight and worked up by pouring the reaction mixture into  
 ice water and adjusted to pH 5 with aqueous 1.0 N HCl and extracted with EtOAc.  
 The extract was washed with NaHCO<sub>3</sub> (aq.), brine, dried (MgSO<sub>4</sub>) and concentrated.  
 15 The residue was purified over Biotage 65M column (EtOAc-hexanes: 5-100%) to  
 provide the product (8.07 g, 84%): Retention time: 1.88 method C) MS *m/z* 639  
 (M<sup>+</sup>+1).

## Step 2:

To a suspension of the product (4.0 g, 6.26 mmol) of Step 1 of Example 384 {Boc - NH-P3(*L-tert*-BuGly)-P2[(4*R*)-(6-methoxy-isoquinoline-1-oxo)-*S*-proline]-P1(1*R*,2*S* Vinyl Acca)-COOEt} in THF(250 mL), CH<sub>3</sub>OH (31 mL), and H<sub>2</sub>O (125 mL) was added LiOH (2.4 g, 100.2 mmol). The reaction mixture was stirred for overnite and then adjusted to pH 7 with aqueous 1.0 N HCl. The organic solvents were removed in vacuo. The aqueous residue was acidified to pH 4 and extracted with EtOAc (2x). The combined organic solvent was dried (Na<sub>2</sub>SO<sub>4</sub>/MgSO<sub>4</sub>), and concentrated in vacuo to supply the product (3.79 g, 99%): <sup>1</sup>H NMR (methanol-d<sub>4</sub>) δ ppm 1.05 (s, 9 H), 1.25 (m, 1 H), 1.29 (s, 9 H), 1.46 (m, 1 H), 1.72 (dd, *J*=8.24, 5.19 Hz, 1 H), 2.23 (q, *J*=8.55 Hz, 1 H), 2.68 (dd, *J*=13.89, 7.78 Hz, 1 H), 3.94 (s, 3 H), 4.05 (dd, *J*=11.60, 3.05 Hz, 1 H), 4.23 (d, *J*=8.85 Hz, 1 H), 4.46 (d, *J*=11.60 Hz, 1 H), 4.63 (t, *J*=8.39 Hz, 1 H), 5.10 (d, *J*=10.38 Hz, 1 H), 5.29 (d, *J*=17.40 Hz, 1 H), 5.85 (m, 2 H), 7.10 (d, *J*=9.16 Hz, 1 H), 7.19 (s, 1 H), 7.26 (d, *J*=5.49 Hz, 1 H), 7.91 (d, *J*=5.80 Hz, 1 H), 8.12 (d, *J*=9.16 Hz, 1 H). LC-MS (Retention time: 1.81 method C) MS *m/z* 611 (M<sup>+</sup>+1).


## Step 3:

A solution of CDI (0.143 g, 0.88 mmol) and the product (0.36 g, 0.59 mmol) of Step 2 of Example 300 {BOCNH-P3(*L-t*-BuGly)-P2[(4*R*)-6-methoxy-sioquinoline-1-oxo)-*S*-proline]-P1(1*R*,2*S* Vinyl Acca)-CO<sub>2</sub>H} in THF (8 mL) was heated at 70 °C for 60 min and allowed to cool down to rt. The reaction solution was evenly divided by syringe into five flasks. To one of the flask was added 4,5-dichloro-thiophene-2-sulfonic acid amide (0.034 g, 0.15 mmol) and followed by the addition of a solution of neat DBU (0.022 mL, 0.15 mmol). The reaction was stirred for overnite, then filtered through syringe filter and purified by preparative HPLC (solvent B: 30% to 100%) and to provide the **Comound 1001** (0.0335 mg); <sup>1</sup>H NMR (500 MHz, Solvent: methanol-d<sub>4</sub>) δ ppm 1.06 (s, 9 H) 1.30 (s, 9 H) 1.40 (m, 1 H) 1.87 (dd, *J*=7.93, 5.49 Hz, 1 H) 2.23 (q, *J*=8.75 Hz, 1 H) 2.31 (m, 1 H) 2.64 (dd, *J*=13.89, 7.17 Hz, 1 H) 3.95 (s, 3 H) 4.08 (m, 1 H) 4.27 (s, 1 H) 4.47 (d, *J*=11.60 Hz, 1 H) 4.57 (dd, *J*=9.61, 7.78 Hz, 1 H) 5.05 (d,

$J=10.38$  Hz, 1 H) 5.25 (d,  $J=17.09$  Hz, 1 H) 5.63 (s, 1 H) 5.85 (s, 1 H) 7.12 (d,  $J=8.85$  Hz, 1 H) 7.21 (s, 1 H) 7.27 (d,  $J=5.80$  Hz, 1 H) 7.66 (s, 1 H) 7.91 (d,  $J=6.10$  Hz, 1 H) 8.12 (d,  $J=9.16$  Hz, 1 H); LC-MS (Retention time: 2.04 method A), MS  $m/z$  824 ( $M^++1$ ).

5

### Example 1002 Preparation of Compound 1002




10

Compound 1002 was prepared in the same procedure as described in **Step 3** of **Example 1001** in preparation of **Compound 1001** instead of 6-Ethoxy-  
 15 benzothiazole-2-sulfonic acid amide (0.038 g, 0.15 mmol), was used in the place of 4,5-dichloro-thiophene-2-sulfonic acid amide, purified by Prep-HPLC (solvent B: 30% to 100%) to provide the the **Compound 1002** (0.0269 mg): <sup>1</sup>H NMR (300 MHz, Solvent methanol- $d_4$ )  $\delta$  ppm 1.04 (s, 9 H) 1.28 (s, 9 H) 1.42 (m, 4 H) 1.77 (dd,  $J=8.05, 5.86$  Hz, 1 H) 2.20 (m, 1 H) 2.30 (m, 1 H) 2.62 (dd,  $J=13.54, 6.95$  Hz, 1 H)  
 20 3.92 (s, 3 H) 4.12 (m, 3 H) 4.26 (s, 1 H) 4.44 (d,  $J=10.98$  Hz, 1 H) 4.56 (dd,  $J=9.33, 7.50$  Hz, 1 H) 4.79 (d,  $J=11.34$  Hz, 1 H) 5.14 (d,  $J=17.57$  Hz, 1 H) 5.40 (m, 1 H) 5.84 (s, 1 H) 7.10 (d,  $J=9.15$  Hz, 1 H) 7.23 (m, 3 H) 7.60 (d,  $J=2.20$  Hz, 1 H) 7.89 (d,

$J=6.22$  Hz, 1 H) 7.96 (d,  $J=8.78$  Hz, 1 H) 8.10 (d,  $J=9.15$  Hz, 1 H); LC-MS (Retention time: 1.97 method A), MS  $m/z$  851 ( $M^++1$ ).

### Example 1003 Preparation of Compound 1003

5




Compound 1003 was prepared in the same procedure as described in **Step 3** of

10 **Example 1001** in preparation of **Compound 1001** instead of 2,4-Dimethyl-thiazole-5-sulfonic acid amide (0.028 g, 0.15 mmol), was used in the place of 4,5-dichloro-thiophene-2-sulfonic acid amide, purified by Prep-HPLC (solvent B: 30% to 100%) to provide the compound 1003 (0.037 mg):  $^1\text{H}$  NMR (500 MHz, DMSO- $D_6$ )  $\delta$  ppm


15 1.05 (s, 9 H) 1.28 (s, 9 H) 1.36 (m, 1 H) 1.78 (d,  $J=6.41$  Hz, 1 H) 2.18 (m, 1 H) 2.27 (m, 1 H) 2.59 (s, 3 H) 2.61 (m, 1 H) 2.66 (s, 3 H) 3.92 (s, 3 H) 4.05 (d,  $J=9.16$  Hz, 1 H) 4.26 (s, 1 H) 4.45 (d,  $J=11.90$  Hz, 1 H) 4.55 (m, 1 H) 4.95 (d,  $J=10.07$  Hz, 1 H) 5.19 (d,  $J=17.09$  Hz, 1 H) 5.40 (m, 1 H) 5.82 (s, 1 H) 7.09 (d,  $J=8.85$  Hz, 1 H) 7.17 (s, 1 H) 7.24 (d,  $J=5.49$  Hz, 1 H) 7.88 (d,  $J=5.80$  Hz, 1 H) 8.09 (d,  $J=9.16$  Hz, 1 H); LC-MS (Retention time: 1.84 method A), MS  $m/z$  785 ( $M^++1$ ).

20

### Example 1004 Preparation of Compound 1004




compound 1004




compound 1004

- 5 Compound 1004 was prepared in the same procedure as described in **Step 3** of **Example 1001** in preparation of **Compound 1001** instead of 5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonic acid amide (0.031 g, 0.15 mmol), was used in the place of 4,5-dichloro-thiophene-2-sulfonic acid amide, purified by Prep-HPLC (solvent B: 30% to 100%) to provide the compound 1004 (0.0662 mg):  $^1\text{H}$  NMR (500 MHz, Solvent methanol- $d_4$ )  $\delta$  ppm 1.05 (s, 9 H) 1.28 (s, 9 H) 1.34 (dd,  $J=9.31, 5.65$  Hz, 1 H) 1.75 (dd,  $J=7.93, 5.80$  Hz, 1 H) 2.14 (m, 1 H) 2.28 (m, 1 H) 2.39 (s, 3 H) 2.61 (dd,  $J=13.58, 6.87$  Hz, 1 H) 3.78 (s, 3 H) 3.92 (s, 3 H) 4.06 (m, 1 H) 4.26 (s, 1 H) 4.44 (d,  $J=10.99$  Hz, 1 H) 4.56 (m, 1 H) 4.92 (dd,  $J=10.38, 1.53$  Hz, 1 H) 5.17 (d,  $J=17.70$  Hz, 1 H) 5.32 (m, 1 H) 5.83 (s, 1 H) 7.09 (d,  $J=10.38$  Hz, 1 H) 7.18 (s, 1 H) 7.25 (d,  $J=6.10$  Hz, 1 H) 7.89 (d,  $J=6.10$  Hz, 1 H) 8.09 (d,  $J=9.16$  Hz, 1 H); LC-MS (Retention time: 1.83 method A), MS  $m/z$  802 ( $M^++1$ ).

#### Example 1005 Preparation of Compound 1005




compound 1005




compound 1005

- 5 Compound 1005 was prepared in the same procedure as described in **Step 3** of **Example 1001** in preparation of **Compound 1001** instead of 1-Methyl-1H-imidazole-4-sulfonic acid amide (0.022 g, 0.15 mmol), was used in the place of 4,5-dichloro-thiophene-2-sulfonic acid amide, purified by Prep-HPLC (solvent B: 30% to 100%) to provide the compound 1005 (0.0251 mg):  $^1\text{H}$  NMR (300 MHz, Solvent
- 10 methanol- $d_4$ )  $\delta$  ppm 1.02 (s, 9 H) 1.28 (s, 9 H) 1.37 (dd,  $J=9.15, 5.49$  Hz, 1 H) 1.75 (dd,  $J=7.87, 5.67$  Hz, 1 H) 2.13 (m, 1 H) 2.29 (m, 1 H) 2.61 (dd,  $J=13.72, 7.14$  Hz, 1 H) 3.78 (s, 3 H) 3.92 (s, 3 H) 4.06 (d,  $J=8.42$  Hz, 1 H) 4.25 (s, 1 H) 4.41 (d,  $J=12.08$  Hz, 1 H) 4.53 (m, 1 H) 4.94 (d,  $J=10.25$  Hz, 1 H) 5.15 (d,  $J=17.20$  Hz, 1 H) 5.42 (m, 1 H) 5.84 (s, 1 H) 7.09 (m, 1 H) 7.18 (s, 1 H) 7.25 (d,  $J=5.86$  Hz, 1 H) 7.70 (s, 1 H)
- 15 7.81 (s, 1 H) 7.89 (d,  $J=5.86$  Hz, 1 H) 8.09 (d,  $J=9.15$  Hz, 1 H); LC-MS (Retention time: 1.69 method A), MS  $m/z$  754 ( $\text{M}^+$ ).

#### Example 1006 Preparation of Compound 1006



compound 1006



compound 1006


5

Compound 1006 was prepared in the same procedure as described in **Step 3** of **Example 1001** in preparation of **Compound 1001** instead of Thiophene-2-sulfonic acid amide


10 (0.022 g, 0.13 mmol), was used in the place of 4,5-dichloro-thiophene-2-sulfonic acid amide, purified by Prep-HPLC (solvent B: 30% to 100%) to provide the compound 1006 (0.0498 mg):  $^1\text{H}$  NMR (500 MHz, BENZENE- $\text{D}_6$ )  $\delta$  ppm 1.04 (s, 9 H) 1.27 (s, 9 H) 1.36 (m, 1 H) 1.77 (m, 1 H) 2.17 (q,  $J=8.65$  Hz, 1 H) 2.25 (m, 1 H) 2.59 (dd,  $J=13.58, 6.87$  Hz, 1 H) 3.91 (s, 3 H) 4.04 (m, 1 H) 4.25 (s, 1 H) 4.43 (d,  $J=11.60$  Hz, 1 H) 4.53 (m, 1 H) 4.96 (d,  $J=10.38$  Hz, 1 H) 5.18 (d,  $J=17.40$  Hz, 1 H) 5.50 (m, 1 H) 5.82 (s, 1 H) 7.11 (m, 2 H) 7.17 (s, 1 H) 7.24 (d,  $J=5.49$  Hz, 1 H) 7.80 (m, 1 H) 7.87 (dd,  $J=9.61, 5.65$  Hz, 2 H) 8.08 (d,  $J=8.85$  Hz, 1 H); LC-MS (Retention time: 1.88 method A), MS  $m/z$  756 ( $\text{M}^{\dagger}+1$ ).

20

Example 1007 Preparation of Compound 1007



compound 1007



compound 1007


Compound 1007 was prepared in the same procedure as described in **Step 3** of

5 **Example 1001** in preparation of **Compound 1001** instead of Benzenesulfonamide (0.0179 g, 0.13 mmol), was used in the place of 4,5-dichloro-thiophene-2-sulfonic acid amide, purified by Prep-HPLC (solvent B: 30% to 100%) to provide the


10 compound 1007 (0.0507 mg):  $^1\text{H}$  NMR (300 MHz, ACETONE- $\text{D}_6$ )  $\delta$  ppm 1.05 (s, 9 H) 1.28 (s, 9 H) 1.34 (dd,  $J=9.33, 5.67$  Hz, 1 H) 1.72 (dd,  $J=7.87, 5.67$  Hz, 1 H) 2.22 (m, 2 H) 2.61 (dd,  $J=13.17, 6.59$  Hz, 1 H) 3.92 (s, 3 H) 4.06 (d,  $J=11.34$  Hz, 1 H) 4.27 (s, 1 H) 4.45 (d,  $J=11.71$  Hz, 1 H) 4.55 (dd,  $J=9.88, 7.32$  Hz, 1 H) 5.17 (d,  $J=17.20$  Hz, 1 H) 5.42 (m, 1 H) 5.83 (s, 1 H) 7.09 (m, 1 H) 7.18 (s, 1 H) 7.25 (d,  $J=5.86$  Hz, 1 H) 7.54 (m, 2 H) 7.66 (t,  $J=7.50$  Hz, 1 H) 7.89 (d,  $J=5.86$  Hz, 1 H) 7.97 (m, 2 H) 8.09 (d,  $J=9.15$  Hz, 1 H); LC-MS (Retention time: 1.89 method A), MS  $m/z$

15 750 ( $\text{M}^++1$ ).

Example 1008 Preparation of Compound 1008




compound 1008




compound 1008

- 5 Compound 1008 was prepared in the same procedure as described in **Step 3** of **Example 1001** in preparation of **Compound 1001** instead of 4-Methoxybenzenesulfonamide (0.025 g, 0.13 mmol), was used in the place of 4,5-dichlorothiophene-2-sulfonic acid amide, purified by Prep-HPLC (solvent B: 30% to 100%) to provide the compound 1008 (0.004 mg):  $^1\text{H}$  NMR (500 MHz, Solvent methanol-  
 10  $\text{d}_4$ )  $\delta$  ppm 1.09 (s, 9 H) 1.31 (s, 9 H) 1.36 (dd,  $J=9.31, 5.34$  Hz, 1 H) 1.74 (dd,  $J=7.93, 5.80$  Hz, 1 H) 2.17 (q,  $J=8.75$  Hz, 1 H) 2.29 (m, 1 H) 2.63 (dd,  $J=13.73, 7.02$  Hz, 1 H) 3.91 (s, 3 H) 3.95 (s, 3 H) 4.09 (d,  $J=11.29$  Hz, 1 H) 4.30 (s, 1 H) 4.47 (d,  $J=11.90$  Hz, 1 H) 4.56 (dd,  $J=9.92, 7.17$  Hz, 1 H) 4.96 (d,  $J=10.38$  Hz, 1 H) 5.20 (d,  $J=17.09$  Hz, 1 H) 5.48 (m, 1 H) 5.86 (s, 1 H) 7.07 (m, 2 H) 7.12 (d,  $J=7.93$  Hz, 1 H)  
 15 7.21 (s, 1 H) 7.28 (d,  $J=5.80$  Hz, 1 H) 7.93 (m, 3 H) 8.12 (d,  $J=8.85$  Hz, 1 H); LC-MS (Retention time: 1.91 method A), MS  $m/z$  780 ( $\text{M}^++1$ ).

#### Example 1009 Preparation of Compound 1009



compound 1009



compound 1009


Compound 1009 was prepared in the same procedure as described in **Step 3** of

5 **Example 1001** in preparation of **Compound 1001** instead of 5-Methyl-pyridine-2-sulfonic acid amide (0.023 g, 0.13 mmol), was used in the place of 4,5-dichloro-thiophene-2-sulfonic acid amide, purified by Prep-HPLC (solvent B: 30% to 100%) to provide the compound 1009 (0.0388 mg):  $^1\text{H}$  NMR (500 MHz, Solvent methanol- $d_4$ )  $\delta$  ppm 1.06 (s, 9 H) 1.31 (s, 9 H) 1.39 (m, 1 H) 1.75 (m, 1 H) 2.18 (m, 1 H) 2.34


10 (m, 1 H) 2.46 (s, 3 H) 2.62 (m, 1 H) 3.95 (s, 3 H) 4.09 (m, 1 H) 4.28 (m, 1 H) 4.45 (d,  $J=10.99$  Hz, 1 H) 4.57 (m, 1 H) 4.93 (d,  $J=10.68$  Hz, 1 H) 5.19 (d,  $J=17.09$  Hz, 1 H) 5.37 (m, 1 H) 5.86 (s, 1 H) 7.12 (d,  $J=8.55$  Hz, 1 H) 7.21 (s, 1 H) 7.28 (d,  $J=5.80$  Hz, 1 H) 7.92 (m, 2 H) 8.01 (d,  $J=5.49$  Hz, 1 H) 8.12 (d,  $J=8.85$  Hz, 1 H) 8.49 (s, 1 H); LC-MS (Retention time: 1.85 method A), MS  $m/z$  765 ( $M^++1$ ).

15

#### Example 1010 Preparation of Compound 1010




compound 1010




Compound 1010 was prepared in the same procedure as described in **Step 3** of **Example 1001** in preparation of **Compound 1001** instead of 6-Chloro-3-methyl-  
 5 benzo[b]thiophene-2-sulfonic acid amide (0.035 g, 0.13 mmol), was used in the place of 4,5-dichloro-thiophene-2-sulfonic acid amide, purified by Prep-HPLC (solvent B: 30% to 100%) to provide the compound 1010 (0.0292 mg):  $^1\text{H}$  NMR (300 MHz, Solvent methanol- $d_4$ )  $\delta$  ppm 1.07 (s, 9 H) 1.29 (s, 9 H) 1.34 (m, 1 H) 1.74 (dd,  $J=7.87, 5.67$  Hz, 1 H) 2.16 (m, 1 H) 2.29 (m, 1 H) 2.62 (m, 1 H) 2.68 (s, 3 H) 3.92 (s, 3 H) 4.06 (m, 1 H) 4.26 (s, 1 H) 4.46 (d,  $J=12.08$  Hz, 1 H) 4.59 (m, 2 H) 5.10 (m, 1 H) 5.22 (m, 1 H) 5.82 (s, 1 H) 7.10 (d,  $J=9.15$  Hz, 1 H) 7.19 (d,  $J=2.20$  Hz, 1 H) 7.25 (d,  $J=5.86$  Hz, 1 H) 7.52 (dd,  $J=8.78, 1.83$  Hz, 1 H) 7.91 (m, 3 H) 8.10 (d,  $J=8.78$  Hz, 1 H); LC-MS (Retention time: 2.12 method A) MS  $m/z$  854 ( $M^++1$ ).

15

#### Example 1011 Preparation of Compound 1011






Compound 1011 was prepared in the same procedure as described in **Step 3** of **Example 1001** in preparation of **Compound 1001** instead N-(5-Sulfamoyl-[1,3,4]thiadiazol-2-yl)-acetamide (0.0179 g, 0.13 mmol), was used in the place of


5 4,5-dichloro-thiophene-2-sulfonic acid amide, purified by Prep-HPLC (solvent B: 30% to 100%) to provide the compound 1011 (0.0388 mg):  $^1\text{H}$  NMR (500 MHz, Solvent methanol- $d_4$ )  $\delta$  ppm 1.03 (s, 9 H) 1.28 (s, 9 H) 1.41 (m, 1 H) 1.81 (dd,  $J=8.24, 5.49$  Hz, 1 H) 2.26 (m, 2 H) 2.28 (s, 3 H) 2.61 (dd,  $J=14.04, 7.02$  Hz, 1 H) 3.92 (s, 3 H) 4.06 (m, 1 H) 4.24 (s, 1 H) 4.43 (d,  $J=11.60$  Hz, 1 H) 4.55 (m, 1 H) 4.99

10 (d,  $J=11.29$  Hz, 1 H) 5.21 (d,  $J=17.09$  Hz, 1 H) 5.52 (m, 1 H) 5.83 (s, 1 H) 7.10 (d,  $J=8.85$  Hz, 1 H) 7.18 (d,  $J=1.83$  Hz, 1 H) 7.25 (d,  $J=6.10$  Hz, 1 H) 7.88 (d,  $J=5.80$  Hz, 1 H) 8.09 (d,  $J=8.85$  Hz, 1 H); LC-MS (Retention time: 1.84 method A), MS  $m/z$  815 ( $M^++1$ ).

15 **Example 1012 Preparation of Compound 1012**



compound 1012



Compound 1012 was prepared in the same procedure as described in **Step 3** of **Example 1001** in preparation of **Compound 1001** instead 3,5-Dimethyl-isoxazole-4-sulfonic acid amide (0.033 g, 0.15 mmol), was used in the place of 4,5-dichloro-

5 thiophene-2-sulfonic acid amide, purified by Prep-HPLC (solvent B: 30% to 100%) to provide the compound 1012 (0.0462 mg): <sup>1</sup>H NMR (500 MHz, Solvent methanol-d<sub>4</sub>) δ ppm 1.08 (s, 9 H) 1.30 (s, 9 H) 1.37 (dd, *J*=9.16, 5.49 Hz, 1 H) 1.80 (m, 1 H) 2.21 (q, *J*=8.55 Hz, 1 H) 2.31 (m, 1 H) 2.40 (s, 3 H) 2.66 (m, 1 H) 2.68 (s, 3 H) 3.95 (s, 3 H) 4.08 (d, *J*=8.85 Hz, 1 H) 4.28 (s, 1 H) 4.48 (d, *J*=11.29 Hz, 1 H) 4.61 (m, 1 H)

10 H) 4.98 (d, *J*=10.38 Hz, 1 H) 5.22 (d, *J*=17.09 Hz, 1 H) 5.36 (m, 1 H) 5.85 (s, 1 H) 7.12 (d, *J*=8.85 Hz, 1 H) 7.21 (s, 1 H) 7.28 (d, *J*=6.10 Hz, 1 H) 7.91 (d, *J*=6.10 Hz, 1 H) 8.13 (d, *J*=9.16 Hz, 1 H); LC-MS (Retention time: 2.05 method A), MS *m/z* 769(M<sup>+</sup>+1).

15

## Section C

### Biological Studies

#### Recombinant HCV NS3/4A protease complex FRET peptide assay

20

The purpose of this in vitro assay was to measure the inhibition of HCV NS3 protease complexes, derived from the BMS strain, H77 strain or J4L6S strain, as described below, by compounds of the present invention. This assay provides an indication of how effective compounds of the present invention would be in inhibiting HCV NS3 proteolytic activity.

25

Serum from an HCV-infected patient was obtained from Dr. T. Wright, San Francisco Hospital. An engineered full-length cDNA (complement deoxyribonucleic acid) template of the HCV genome (BMS strain) was constructed from DNA

fragments obtained by reverse transcription-PCR (RT-PCR) of serum RNA (ribonucleic acid) and using primers selected on the basis of homology between other genotype 1a strains. From the determination of the entire genome sequence, a genotype 1a was assigned to the HCV isolate according to the classification of  
5 Simmonds et al. (See P Simmonds, KA Rose, S Graham, SW Chan, F McOmish, BC Dow, EA Follett, PL Yap and H Marsden, *J. Clin. Microbiol.*, 31(6), 1493-1503 (1993)). The amino acid sequence of the nonstructural region, NS2-5B, was shown to be >97% identical to HCV genotype 1a (H77) and 87% identical to genotype 1b (J4L6S). The infectious clones, H77 (1a genotype) and J4L6S (1b genotype) were  
10 obtained from R. Purcell (NIH) and the sequences are published in Genbank (AAB67036, see Yanagi, M., Purcell, R.H., Emerson, S.U. and Bukh, J. *Proc. Natl. Acad. Sci. U.S.A.* 94(16), 8738-8743 (1997); AF054247, see Yanagi, M., St Claire, M., Shapiro, M., Emerson, S.U., Purcell, R.H. and Bukh, J. *Virology* 244 (1), 161-172. (1998)).

15  
The H77 and J4L6S strains were used for production of recombinant NS3/4A protease complexes. DNA encoding the recombinant HCV NS3/4A protease complex (amino acids 1027 to 1711) for these strains were manipulated as described by P. Gallinari et al. (see Gallinari P, Paolini C, Brennan D, Nardi C, Steinkuhler C,  
20 De Francesco R. *Biochemistry*. 38(17):5620-32, (1999)). Briefly, a three-lysine solubilizing tail was added at the 3'-end of the NS4A coding region. The cysteine in the P1 position of the NS4A-NS4B cleavage site (amino acid 1711) was changed to a glycine to avoid the proteolytic cleavage of the lysine tag. Furthermore, a cysteine to serine mutation was introduced by PCR at amino acid position 1454 to prevent the  
25 autolytic cleavage in the NS3 helicase domain. The variant DNA fragment was cloned in the pET21b bacterial expression vector (Novagen) and the NS3/4A complex was expressed in *Escherichia. coli* strain BL21 (DE3) (Invitrogen) following the protocol described by P. Gallinari et al. (see Gallinari P, Brennan D, Nardi C, Brunetti M, Tomei L, Steinkuhler C, De Francesco R., *J Virol.* 72(8):6758-  
30 69 (1998)) with modifications. Briefly, the NS3/4A protease complex expression was induced with 0.5 millimolar (mM) Isopropyl  $\beta$ -D-1-thiogalactopyranoside (IPTG) for 22 hours (h) at 20°C. A typical fermentation (1 Liter (L)) yielded approximately 10 grams (g) of wet cell paste. The cells were resuspended in lysis

buffer (10 mL/g) consisting of 25 mM N-(2-Hydroxyethyl)Piperazine-N'-(2-Ethane Sulfonic acid) (HEPES), pH 7.5, 20% glycerol, 500 mM Sodium Chloride (NaCl), 0.5% Triton X-100, 1 microgram/milliliter ("µg/mL") lysozyme, 5 mM Magnesium Chloride (MgCl<sub>2</sub>), 1 µg/ml DnaseI, 5mM β-Mercaptoethanol (βME), Protease  
5 inhibitor - Ethylenediamine Tetraacetic acid (EDTA) free (Roche), homogenized and incubated for 20 minutes (min) at 4°C. The homogenate was sonicated and clarified by ultra-centrifugation at 235000 g for 1 h at 4°C. Imidazole was added to the supernatant to a final concentration of 15 mM and the pH adjusted to 8.0. The crude protein extract was loaded on a Nickel - Nitrilotriacetic acid (Ni-NTA) column pre-  
10 equilibrated with buffer B (25 mM HEPES, pH 8.0, 20% glycerol, 500 mM NaCl, 0.5% Triton X-100, 15 mM imidazole, 5 mM βME). The sample was loaded at a flow rate of 1 mL/min. The column was washed with 15 column volumes of buffer C (same as buffer B except with 0.2% Triton X-100). The protein was eluted with 5 column volumes of buffer D (same as buffer C except with 200 mM Imidazole).

15

NS3/4A protease complex-containing fractions were pooled and loaded on a desalting column Superdex-S200 pre-equilibrated with buffer D (25mM HEPES, pH 7.5, 20% glycerol, 300 mM NaCl, 0.2% Triton X-100, 10 mM βME). Sample was loaded at a flow rate of 1 mL/min. NS3/4A protease complex-containing fractions  
20 were pooled and concentrated to approximately 0.5 mg/ml. The purity of the NS3/4A protease complexes, derived from the BMS, H77 and J4L6S strains, were judged to be greater than 90% by SDS-PAGE and mass spectrometry analyses.

The enzyme was stored at -80°C, thawed on ice and diluted prior to use in  
25 assay buffer. The substrate used for the NS3/4A protease assay was RET S1 (Resonance Energy Transfer Depsipeptide Substrate; AnaSpec, Inc. cat # 22991)(FRET peptide), described by Taliani et al. in *Anal. Biochem.* 240(2):60-67 (1996). The sequence of this peptide is loosely based on the NS4A/NS4B natural cleavage site for the HCV NS3 protease except there is an ester linkage rather than an  
30 amide bond at the cleavage site. The peptide substrate was incubated with one of the three recombinant NS3/4A protease complexes, in the absence or presence of a

compound of the present invention, and the formation of fluorescent reaction product was followed in real time using a Cytofluor Series 4000.

The reagents were as follow: HEPES and Glycerol (Ultrapure) were obtained  
5 from GIBCO-BRL. Dimethyl Sulfoxide (DMSO) was obtained from Sigma.  $\beta$ -Mercaptoethanol was obtained from Bio Rad.

Assay buffer: 50 mM HEPES, pH 7.5; 0.15 M NaCl; 0.1% Triton; 15% Glycerol; 10  
mM  $\beta$ ME. Substrate: 2  $\mu$ M final concentration (from a 2 mM stock solution in  
10 DMSO stored at -20°C). HCV NS3/4A protease type 1a (1b), 2-3 nM final  
concentration (from a 5  $\mu$ M stock solution in 25 mM HEPES, pH 7.5, 20% glycerol,  
300 mM NaCl, 0.2% Triton-X100, 10 mM  $\beta$ ME). For compounds with potencies  
approaching the assay limit, the assay was made more sensitive by adding 50  $\mu$ g/ml  
Bovine Serum Albumin (Sigma) to the assay buffer and reducing the end protease  
15 concentration to 300 pM.

The assay was performed in a 96-well polystyrene black plate from Falcon.  
Each well contained 25  $\mu$ l NS3/4A protease complex in assay buffer, 50  $\mu$ l of a  
compound of the present invention in 10% DMSO/assay buffer and 25  $\mu$ l substrate in  
20 assay buffer. A control (no compound) was also prepared on the same assay plate.  
The enzyme complex was mixed with compound or control solution for 1 min before  
initiating the enzymatic reaction by the addition of substrate. The assay plate was  
read immediately using the Cytofluor Series 4000 (Perspective Biosystems). The  
instrument was set to read an emission of 340 nm and excitation of 490 nm at 25°C.  
25 Reactions were generally followed for approximately 15 min.

The percent inhibition was calculated with the following equation:

$$100 - [(\delta F_{inh}/\delta F_{con}) \times 100]$$

30

where  $\delta F$  is the change in fluorescence over the linear range of the curve. A non-linear curve fit was applied to the inhibition-concentration data, and the 50%

effective concentration (IC<sub>50</sub>) was calculated by the use of Excel XI-fit software using the equation,  $y=A+((B-A)/(1+((C/x)^D)))$ .

All of the compounds tested were found to inhibit the activity of the NS3/4A protease complex with IC<sub>50</sub>'s of 1.2 μM or less. Further, compounds of the present invention, which were tested against more than one type of NS3/4A complex, were found to have similar inhibitory properties though the compounds uniformly demonstrated greater potency against the 1b strains as compared to the 1a strains.

### Specificity Assays

The specificity assays were performed to demonstrate the *in vitro* selectivity of the compounds of the present invention in inhibiting HCV NS3/4A protease complex as compared to other serine or cysteine proteases.

The specificities of compounds of the present invention were determined against a variety of serine proteases: human neutrophil elastase (HNE), porcine pancreatic elastase (PPE) and human pancreatic chymotrypsin and one cysteine protease: human liver cathepsin B. In all cases a 96-well plate format protocol using colorimetric p-nitroaniline (pNA) substrate specific for each enzyme was used as described previously (PCT Patent Application No. WO 00/09543) with some modifications to the serine protease assays. All enzymes were purchased from Sigma while the substrates were from Bachem.

Each assay included a 2 h enzyme-inhibitor pre-incubation at room temperature followed by addition of substrate and hydrolysis to ~30% conversion as measured on a Spectramax Pro microplate reader. Compound concentrations varied from 100 to 0.4 μM depending on their potency.

The final conditions for each assay were as follows:

50 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) pH 8, 0.5 M Sodium Sulfate (Na<sub>2</sub>SO<sub>4</sub>), 50 mM NaCl, 0.1 mM EDTA, 3% DMSO, 0.01% Tween-20 with:

133  $\mu$ M succ-AAA-pNA and 20 nM HNE or 8 nM PPE; 100  $\mu$ M succ-AAPF-pNA and 250 pM Chymotrypsin.

100 mM NaHPO<sub>4</sub> (Sodium Hydrogen Phosphate) pH 6, 0.1 mM EDTA, 3%  
5 DMSO, 1 mM TCEP (Tris(2-carboxyethyl)phosphine hydrochloride), 0.01%  
Tween-20, 30  $\mu$ M Z-FR-pNA and 5 nM Cathepsin B (enzyme stock activated  
in buffer containing 20 mM TCEP before use).

The percentage of inhibition was calculated using the formula:

10

$$[1 - ((UV_{inh} - UV_{blank}) / (UV_{ctl} - UV_{blank}))] \times 100$$

A non-linear curve fit was applied to the inhibition-concentration data, and  
the 50% effective concentration (IC<sub>50</sub>) was calculated by the use of Excel XI-fit  
15 software.

### **Generation of HCV Replicon**

20 An HCV replicon whole cell system was established as described by  
Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R., Science  
285(5424):110-3 (1999). This system enabled us to evaluate the effects of our HCV  
Protease compounds on HCV RNA replication. Briefly, using the HCV strain 1b  
sequence described in the Lohmann paper (Assession number:AJ238799), an HCV  
25 cDNA was generated encoding the 5' internal ribosome entry site (IRES), the  
neomycin resistance gene, the EMCV (encephalomyocarditis viurs)-IRES and the  
HCV nonstructural proteins, NS3-NS5B, and 3' non-translated region (NTR). In  
vitro transcripts of the cDNA were transfected into the human hepatoma cell line,  
Huh7. Selection for cells constitutively expressing the HCV replicon was achieved  
30 in the presence of the selectable marker, neomycin (G418). Resulting cell lines were  
characterized for positive and negative strand RNA production and protein  
production over time.

### FRET Assay

Huh7 cells, constitutively expressing the HCV replicon, were grown in Dulbecco's Modified Eagle Media (DMEM) containing 10% Fetal calf serum (FCS) and 1 mg/ml G418 (Gibco-BRL). Cells were seeded the night before ( $1.5 \times 10^4$  cells/well) in 96-well tissue-culture sterile plates. Compound and no compound controls were prepared in DMEM containing 4% FCS, 1:100 Penicillin / Streptomycin, 1:100 L-glutamine and 5% DMSO in the dilution plate (0.5% DMSO final concentration in the assay). Compound / DMSO mixes were added to the cells and incubated for 4 days at 37°C. After 4 days, plates were rinsed thoroughly with Phosphate-Buffered Saline (PBS) (3 times 150  $\mu$ l). The cells were lysed with 25  $\mu$ l of a lysis assay reagent containing the FRET peptide (RET S1, as described for the in vitro enzyme assay). The lysis assay reagent was made from 5X cell Luciferase cell culture lysis reagent (Promega #E153A) diluted to 1X with distilled water, NaCl added to 150 mM final, the FRET peptide diluted to 10  $\mu$ M final from a 2 mM stock in 100% DMSO. The plate was then placed into the Cytofluor 4000 instrument which had been set to 340 nm excitation / 490 nm emission, automatic mode for 21 cycles and the plate read in a kinetic mode.  $EC_{50}$  determinations were carried out as described for the  $IC_{50}$  determinations.

20

### Luciferase Assay

As a secondary assay,  $EC_{50}$  determinations from the replicon FRET assay were confirmed in a luciferase reporter assay. Utilization of a replicon luciferase reporter assay was first described by Krieger et al (Krieger N, Lohmann V, and Bartenschlager R, J. Virol. 75(10):4614-4624 (2001)). The replicon construct described for our FRET assay was modified by replacing the resistance gene neomycin with the Blasticidin-resistance gene fused to the N-terminus of the humanized form of Renilla luciferase (restriction sites Asc1 / Pme1 used for the subcloning). The adaptive mutation at position 1179 (serine to isoleucine) was also introduced (Blight KJ, Kolykhalov, AA, Rice, CM, Science 290(5498):1972-1974). The luciferase reporter assay was set up by seeding huh7 cells the night before at a

30

density of  $2 \times 10^6$  cells per T75 flask. Cells were washed the next day with 7.5 ml Opti-MEM. Following the Invitrogen protocol, 40  $\mu$ l DMRIE-C was vortexed with 5 ml Opti-MEM before adding 5  $\mu$ g HCV reporter replicon RNA. The mix was added to the washed huh7 cells and left for 4 h at 37°C. In the mean time, serial compound dilutions and no compound controls were prepared in DMEM containing 10% FCS and 5% DMSO in the dilution plate (0.5% DMSO final concentration in the assay). Compound / DMSO mixes were added to each well of a 24-well plate. After 4 h, the transfection mix was aspirated, and cells washed with 5 ml of Opti-MEM before trypsinization. Trypsinized cells were resuspended in 10% DMEM and seeded at  $2 \times 10^4$  cells/well in the 24-well plates containing compound or no compound controls. Plates were incubated for 4 days. After 4 days, media was removed and cells washed with PBS. 100  $\mu$ l 1x Renilla Luciferase Lysis Buffer (Promega) was immediately added to each well and the plates either frozen at -80°C for later analysis, or assayed after 15 min of lysis. Lysate (40  $\mu$ l) from each well was transferred to a 96-well black plate (clear bottom) followed by 200  $\mu$ l 1x Renilla Luciferase assay substrate. Plates were read immediately on a Packard TopCount NXT using a luminescence program.

The percentage inhibition was calculated using the formula below:

$$\% \text{ control} = \frac{\text{average luciferase signal in experimental wells (+ compound)}}{\text{average luciferase signal in DMSO control wells (- compound)}}$$

The values were graphed and analyzed using XLFit to obtain the EC<sub>50</sub> value.

25

Compounds in accordance with the present invention were tested for biological activity as described above and found to have activities in the ranges as follow:

30 IC<sub>50</sub> Activity Ranges (NS3/4A BMS Strain): A is 10 – 100 micromolar ( $\mu$ M); B is 1 - 10  $\mu$ M; C is 0.1 - 1  $\mu$ M; D is <0.1  $\mu$ M

EC50 Activity Range (for compounds tested): A is 10 - 100  $\mu\text{M}$ ; B is 1 - 10  $\mu\text{M}$ ; C is 0.1 - 1  $\mu\text{M}$ ; D is  $<0.1\mu\text{M}$

Note that by using the Patent example number and the Patent compound number shown in Table 2, the structures of compounds can be found herein.

5

In accordance with the present invention, preferably the compounds have a biological activity ( $\text{EC}_{50}$ ) of 10  $\mu\text{M}$  or less, more preferably 1  $\mu\text{M}$  or less and most preferably 100 nM or less.

10

Table 2 Biological activity


Example & Compound Number	IC50 ( $\mu\text{M}$ )	EC50 ( $\mu\text{M}$ )
Example 1001 Compound 1001	D	B
Ex. 1002, Cmpd. 1002	C	B
Ex. 1003, Cmpd. 1003	C	C
Ex. 1004, Cmpd. 1004	C	C
Ex. 1005, Cmpd. 1005	B	B
Ex.1006, Cmpd. 1006	D	C

Ex. 1007, Cmpd. 1007	D	C
Ex. 1008, Cmpd. 1008	D	C
Ex. 1009, Cmpd. 1009	C	B
Ex. 1010, Cmpd. 1010	B	
Ex. 1011, Cmpd. 1011	D	B
Ex. 1012, Cmpd. 1012	B	

Those skilled in the art will recognize that although the invention has been described above with respect to specific aspects, other aspects are intended to be  
5 within the scope of the claims which follow. All documents referenced herein are hereby incorporated by reference as if set out in full.

CLAIMS

1. A compound having the formula



5














wherein:


- (a)  $R_1$  is Het or aryl;
- (b)  $m$  is 1 or 2;
- 10 (c)  $n$  is 1 or 2;
- (d)  $R_2$  is H; or  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{3-7}$  cycloalkyl, each optionally substituted with halogen;
- (e)  $R_3$  is  $C_{1-8}$  alkyl optionally substituted with halo, cyano, amino,  $C_{1-6}$  dialkylamino,  $C_{6-10}$  aryl,  $C_{7-14}$  alkylaryl,  $C_{1-6}$  alkoxy, carboxy, hydroxy, aryloxy,  $C_{7-14}$  alkylaryloxy,  $C_{2-6}$  alkylester or  $C_{8-15}$  alkylarylester;  $C_{3-12}$  alkenyl,  $C_{3-7}$  cycloalkyl, or  $C_{4-10}$  alkylcycloalkyl, wherein the cycloalkyl or alkylcycloalkyl are optionally substituted with hydroxy,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{1-6}$  alkoxy; or  $R_3$  together with the carbon atom to which it is attached forms a  $C_{3-7}$  cycloalkyl group optionally substituted with  $C_{2-6}$  alkenyl;
- 15 (f)  $Y$  is H, phenyl substituted with nitro, pyridyl substituted with nitro, or  $C_{1-6}$  alkyl optionally substituted with cyano, OH or  $C_{3-7}$  cycloalkyl; provided that if  $R_4$  or  $R_5$  is H then  $Y$  is H;
- (g)  $B$  is H,  $C_{1-6}$  alkyl,  $R_4-(C=O)-$ ,  $R_4O(C=O)-$ ,  $R_4-N(R_5)-C(=O)-$ ,  $R_4-N(R_5)-C(=S)-$ ,  $R_4SO_2-$ , or  $R_4-N(R_5)-SO_2-$ ;
- 20 (h)  $R_4$  is (i)  $C_{1-10}$  alkyl optionally substituted with phenyl, carboxyl,  $C_{1-6}$  alkanoyl, 1-3 halogen, hydroxy,  $-OC(O)C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amino
- 25

- optionally substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl) amido;  
(ii) C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkoxy, or C<sub>4-10</sub> alkylcycloalkyl, each  
optionally substituted with hydroxy, carboxyl, (C<sub>1-6</sub> alkoxy)carbonyl,  
amino optionally substituted with C<sub>1-6</sub> alkyl, amido, or (lower alkyl)  
5 amido; (iii) C<sub>6-10</sub> aryl or C<sub>7-16</sub> arylalkyl, each optionally substituted  
with C<sub>1-6</sub> alkyl, halogen, nitro, hydroxy, amido, (lower alkyl) amido,  
or amino optionally substituted with C<sub>1-6</sub> alkyl; (iv) Het; (v)  
bicyclo(1.1.1)pentane; or (vi) -C(O)OC<sub>1-6</sub> alkyl, C<sub>2-6</sub>alkenyl or C<sub>2-6</sub>  
alkynyl;
- 10 (i) R<sub>5</sub> is H; C<sub>1-6</sub> alkyl optionally substituted with 1-3 halogens; or C<sub>1-6</sub>  
alkoxy provided R<sub>4</sub> is C<sub>1-10</sub> alkyl;
- (j) X is O, S, SO, SO<sub>2</sub>, OCH<sub>2</sub>, CH<sub>2</sub>O or NH;
- (k) R' is Het, C<sub>6-10</sub> aryl or C<sub>7-14</sub> alkylaryl, each optionally substituted with  
R<sup>a</sup>; and
- 15 (l) R<sup>a</sup> is C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-6</sub> alkoxy, C<sub>3-7</sub> cycloalkoxy, halo-C<sub>1-6</sub>  
alkyl, CF<sub>3</sub>, mono-or di- halo-C<sub>1-6</sub> alkoxy, cyano, halo, thioalkyl,  
hydroxy, alkanoyl, NO<sub>2</sub>, SH, , amino, C<sub>1-6</sub> alkylamino, di (C<sub>1-6</sub>)  
alkylamino, di (C<sub>1-6</sub>) alkylamide, carboxyl, (C<sub>1-6</sub>) carboxyester, C<sub>1-6</sub>  
alkylsulfone, C<sub>1-6</sub> alkylsulfonamide, di (C<sub>1-6</sub>) alkyl(alkoxy)amine, C<sub>6-</sub>  
20 <sub>10</sub> aryl, C<sub>7-14</sub> alkylaryl, or a 5-7 membered monocyclic heterocycle;

or a pharmaceutically acceptable enantiomer, diastereomer, salt, solvate or prodrug thereof.

- 25 2. A compound of Claim 1 wherein R<sub>1</sub> is






3. The compound of Claim 1 wherein  $R_2$  is  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{3-7}$  cycloalkyl.
- 5
4. The compound of Claim 3 wherein  $R_2$  is  $C_{2-6}$  alkenyl.
5. The compound of Claim 1 wherein  $R_3$  is  $C_{1-8}$  alkyl optionally substituted with  $C_6$ aryl,  $C_{1-6}$  alkoxy, carboxy, hydroxy, aryloxy,  $C_{7-14}$  alkylaryloxy,  $C_{2-6}$  alkylester or  $C_{8-15}$  alkylarylester;  $C_{3-12}$  alkenyl;  $C_{3-7}$  cycloalkyl; or  $C_{4-10}$  alkylcycloalkyl.
- 10
6. The compound of Claim 5 wherein  $R_3$  is  $C_{1-8}$  alkyl optionally substituted with  $C_{1-6}$  alkoxy; or  $C_{3-7}$  cycloalkyl.
- 15
7. The compound of Claim 1 wherein Y is H.
8. The compound of Claim 1 wherein B is H,  $C_{1-6}$  alkyl,  $R_4-(C=O)-$ ,  $R_4O(C=O)-$ ,  $R_4-N(R_5)-C(=O)-$ ,  $R_4-N(R_5)-C(=S)-$ ,  $R_4SO_2-$ , or  $R_4-N(R_5)-SO_2-$ .
- 20
9. The compound of Claim 8 wherein B is  $R_4-(C=O)-$ ,  $R_4O(C=O)-$ , or  $R_4-N(R_5)-C(=O)-$ .
10. The compound of Claim 9 wherein B is  $R_4O(C=O)-$  and  $R_4$  is  $C_{1-6}$  alkyl.
- 25
11. The compound of Claim 1 wherein  $R_4$  is (i)  $C_{1-10}$  alkyl optionally substituted

with phenyl, carboxyl, C<sub>1-6</sub> alkanoyl, 1-3 halogen, hydroxy, C<sub>1-6</sub> alkoxy; (ii) C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkoxy, or C<sub>4-10</sub> alkylcycloalkyl; or (iii) C<sub>6-10</sub> aryl or C<sub>7-16</sub> arylalkyl, each optionally substituted with C<sub>1-6</sub> alkyl or halogen.


- 5 12. The compound of Claim 11 wherein R<sub>4</sub> is (i) C<sub>1-10</sub> alkyl optionally substituted with 1-3 halogen or C<sub>1-6</sub> alkoxy; or (ii) C<sub>3-7</sub> cycloalkyl or C<sub>4-10</sub> alkylcycloalkyl.
- 10 13. The compound of Claim 1 wherein R<sub>5</sub> is H or C<sub>1-6</sub> alkyl optionally substituted with 1-3 halogens.
14. The compound of Claim 13 wherein R<sub>5</sub> is H.
- 15 15. The compound of Claim 1 wherein X is O or NH.
16. The compound of Claim 1 wherein R' is Het or C<sub>6-10</sub> aryl each optionally substituted with R<sup>a</sup>.
- 20 17. The compound of Claim 16 wherein R' is Het.
18. The compound of Claim 17 wherein the heterocycle contains 1 or 2 nitrogen atoms and optionally a sulfur atom or an oxygen atom in the ring.
- 25 19. The compound of Claim 18 wherein the heterocycle is substituted with at least one of C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, halo, C<sub>6-10</sub> aryl, C<sub>7-14</sub> alkylaryl, or a 5-7 membered monocyclic heterocycle.
- 30 20. The compound of Claim 1 wherein R<sup>a</sup> is C<sub>1-6</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-6</sub> alkoxy, halo-C<sub>1-6</sub> alkyl, halo, amino, C<sub>6</sub> aryl, or a 5-7 membered monocyclic heterocycle.
21. A compound having the formula



wherein:

- 5 (a)  $R_1$  is unsubstituted Het or Het substituted with from one to three of halo, cyano, trifluoromethyl,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amido,  $C_{1-6}$  amino, phenyl, said phenyl being unsubstituted or substituted with one to three substituents selected from halo, cyano, nitro,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amido or phenyl; or a monocyclic aryl;
- 10 (b)  $R_2$  is  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl or  $C_{3-7}$  cycloalkyl;
- (c)  $R_3$  is  $C_{1-8}$  alkyl optionally substituted with  $C_6$  aryl,  $C_{1-6}$  alkoxy, carboxy, hydroxy, aryloxy,  $C_{7-14}$  alkylaryloxy,  $C_{2-6}$  alkylester,  $C_{8-15}$  alkylarylester;  $C_{3-12}$  alkenyl,  $C_{3-7}$  cycloalkyl, or  $C_{4-10}$  alkylcycloalkyl;
- (d) B is H,  $C_{1-6}$  alkyl,  $R_4-(C=O)-$ ,  $R_4O(C=O)-$ ,  $R_4-N(R_5)-C(=O)-$ ,  $R_4-N(R_5)-C(=S)-$ ,  $R_4SO_2-$ , or  $R_4-N(R_5)-SO_2-$ ;
- 15 (e)  $R_4$  is (i)  $C_{1-10}$  alkyl optionally substituted with phenyl, carboxyl,  $C_{1-6}$  alkanoyl, 1-3 halogen, hydroxy,  $C_{1-6}$  alkoxy; (ii)  $C_{3-7}$  cycloalkyl,  $C_{3-7}$  cycloalkoxy, or  $C_{4-10}$  alkylcycloalkyl; or (iii)  $C_{6-10}$  aryl or  $C_{7-16}$  arylalkyl, each optionally substituted with  $C_{1-6}$  alkyl or halogen;
- (f)  $R_5$  is H or  $C_{1-6}$  alkyl optionally substituted with 1-3 halogens;
- 20 (g) X is O or NH;
- (h)  $R'$  is Het; or  $C_{6-10}$  aryl optionally substituted with  $R^a$ ; and
- (i)  $R^a$  is  $C_{1-6}$  alkyl,  $C_{3-7}$  cycloalkyl,  $C_{1-6}$  alkoxy, halo- $C_{1-6}$  alkyl, halo, amino,  $C_6$  aryl, or a 5-7 membered monocyclic heterocycle;
- 25 or a pharmaceutically acceptable enantiomer, diastereomer, salt, solvate or prodrug thereof.

22. The compound of Claim 21 wherein R' is a bicyclic heterocycle.
23. The compound of Claim 22 wherein the heterocycle contains 1 or 2 nitrogen  
5 atoms and optionally a sulfur atom or an oxygen atom in the ring.
24. The compound of Claim 22 wherein the heterocycle is substituted with at  
least one of C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, halo, C<sub>6</sub> aryl, and a 5-7 membered monocyclic  
heterocycle.  
10
25. The compound of Claim 21 wherein R' is a bicyclic heterocycle containing 1  
nitrogen atom and substituted with methoxy and at least one of a C<sub>6</sub> aryl and a 5-7  
membered monocyclic heterocycle.
- 15 26. The compound of Claim 21 wherein R' is a monocyclic heterocycle.
27. The compound of Claim 26 wherein the heterocycle contains 1 or 2 nitrogen  
atoms and optionally a sulfur atom or an oxygen atom in the ring.
- 20 28. The compound of Claim 26 wherein the heterocycle is substituted with at  
least one of C<sub>1-6</sub> alkyl, C<sub>1-6</sub> alkoxy, halo, C<sub>6-10</sub> aryl, C<sub>7-14</sub> alkylaryl, or a 5-7 membered  
monocyclic heterocycle.
- 25 29. The compound of Claim 21 wherein R' is a monocyclic heterocycle containing  
1 or 2 nitrogen atoms and substituted with methoxy and at least one of a C<sub>6</sub> aryl and  
a 5-7 membered monocyclic heterocycle.
30. A compound having the formula



(III)

wherein:

- 5 (a)  $R_1$  is unsubstituted Het or Het substituted with one to three of halo, cyano, trifluoromethyl,  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, amido, or amino; or a  $C_6$  aryl;
- (b)  $R_2$  is  $C_{2-6}$  alkenyl;
- (c)  $R_3$  is  $C_{1-8}$  alkyl;
- (d) B is  $R_4O(C=O)-$ , or  $R_4-N(H)-C(=O)-$ ;
- 10 (e)  $R_4$  is  $C_{1-10}$  alkyl;
- (f)  $R'$  is a bicyclic heterocycle optionally substituted with  $R^a$ ; and
- (g)  $R^a$  is  $C_{1-6}$  alkyl,  $C_{1-6}$  alkoxy, halo,  $C_6$  aryl, or a 5-7 membered monocyclic heterocycle;
- 15 or a pharmaceutically acceptable enantiomer, diastereomer, salt, solvate or prodrug thereof.

31. The compound of Claim 30 wherein  $R_2$  is vinyl.
- 20 32. The compound of Claim 30 wherein  $R_3$  is t-butyl.
33. The compound of Claim 30 wherein  $R_4$  is t-butyl.
- 25 34. The compound of Claim 30 wherein  $R'$  is quinoline or isoquinoline optionally

substituted with R<sup>a</sup>.

35. The compound of Claim 30 wherein R<sub>2</sub> is vinyl, R<sub>3</sub> is t-butyl, R<sub>4</sub> is t-butyl, and R' is isoquinoline substituted with R<sup>a</sup>.
- 5
36. The compound of Claim 35 wherein R<sup>a</sup> is C<sub>1-6</sub> alkoxy.
37. The compound of Claim 36 wherein R<sup>a</sup> further includes at least one of C<sub>6</sub> aryl or a 5-7 membered monocyclic heterocycle.
- 10
38. A composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
39. The composition according to Claim 38 further comprising a compound
- 15 having anti-HCV activity.
40. The composition according to Claim 39 wherein the compound having anti-HCV activity is an interferon.
- 20
41. The composition according to Claim 40 wherein the interferon is selected from the group consisting of interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, and lymphoblastoid interferon tau.
42. The composition according to Claim 39 wherein the compound having anti-
- 25 HCV activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.
- 30
43. The composition according to the Claim 38 further comprising an interferon and ribavirin.
44. The composition according to Claim 39 wherein the compound having anti-

HCV activity is a small molecule compound.

45. The composition according to Claim 39 wherein the compound having anti-HCV activity is effective to inhibit the function of a target selected from the group  
5 consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A protein, IMPDH and a nucleoside analog for the treatment of an HCV infection.

46. A method of inhibiting the function of the HCV serine protease  
10 comprising contacting the HCV serine protease with the compound of Claim 1.

47. A method of treating an HCV infection in a patient, comprising administering to the patient a therapeutically effective amount of the compound of Claim 1, or a pharmaceutically acceptable enantiomer, diastereomer, solvate, prodrug or salt  
15 thereof.

48. The method according to Claim 47 wherein the compound is effective to inhibit the function of the HCV serine protease.

20 49. The method according to Claim 47 further comprising administering another compound having anti-HCV activity prior to, after or simultaneously with the compound of Claim 1.

50. The method according to Claim 49 wherein the other compound having anti-  
25 HCV activity is an interferon.

51. The method according to Claim 50 wherein the interferon is selected from the group consisting of interferon alpha 2B, pegylated interferon alpha, consensus interferon, interferon alpha 2A, lymphoblastiod interferon tau.  
30

52. The method according to Claim 49 wherein the other compound having anti-HCV activity is selected from the group consisting of interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type 1 helper T cell

response, interfering RNA, anti-sense RNA, Imiqimod, ribavirin, an inosine 5'-monophosphate dehydrogenase inhibitor, amantadine, and rimantadine.

53. The method according to Claim 52 wherein the compound having anti-HCV  
5 activity is a small molecule.

54. The method according to Claim 53 wherein the compound having anti-HCV  
activity is effective to inhibit the function of a target selected from the group  
consisting of HCV metalloprotease, HCV serine protease, HCV polymerase, HCV  
10 helicase, HCV NS4B protein, HCV entry, HCV assembly, HCV egress, HCV NS5A  
protein, IMPDH and a nucleoside analog for the treatment of an HCV infection.

55. The method according to Claim 49 wherein the other compound having anti-  
HCV activity is effective to inhibit the function of target in the HCV life cycle other  
15 than the HCV serine protease.

56. Use of the compound of Claim 1 for the manufacture of a medicament for  
treating HCV infection in a patient.

20 57. Use of the composition of Claim 38 for the manufacture of a medicament for  
treating HCV infection in a patient.